[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4793
1. Kishikawa M, Koyama K, Iseki M, Kobuke T, Yonehara S, Soda M, Ron E, Tokunaga M, Preston DL, Mabuchi K, Tokuoka S: Histologic characteristics of skin cancer in Hiroshima and Nagasaki: background incidence and radiation effects. Int J Cancer; 2005 Nov 10;117(3):363-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Skin tumor incident cases diagnosed between 1958 and 1987 were ascertained by linkage to the Hiroshima and Nagasaki tumor registries augmented by searches of other data sources.
  • Study pathologists reviewed tumor specimens and pathology reports and classified tumors using the World Health Organization classification scheme.
  • They identified 274 primary incident skin cancers, of which 106 were basal cell carcinoma (BCC), 81 were squamous cell carcinoma (SCC), and 14 were malignant melanomas.
  • [MeSH-major] Nuclear Warfare. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Female. Humans. Incidence. Japan / epidemiology. Male. Middle Aged. Neoplasms, Radiation-Induced. Radioactive Fallout

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15900592.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CP / N01-CP-31012; United States / NCI NIH HHS / CP / N01-CP-71015
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radioactive Fallout
  •  go-up   go-down


2. Tsiliboti D, Antonopoulos D, Spyropoulos K, Naxakis S, Goumas P: Total nasal reconstruction using a prelaminated free radial forearm flap and porous polyethylene implants. J Reconstr Microsurg; 2008 Aug;24(6):449-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Neoplasm Recurrence, Local / surgery. Nose Neoplasms / surgery. Polyethylene. Rhinoplasty / methods. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. POLYETHYLENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688765.001).
  • [ISSN] 0743-684X
  • [Journal-full-title] Journal of reconstructive microsurgery
  • [ISO-abbreviation] J Reconstr Microsurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-88-4 / Polyethylene
  •  go-up   go-down


3. Younis LK, El Sakka H, Haque I: The Prognostic Value of E-cadherin Expression in Breast Cancer. Int J Health Sci (Qassim); 2007 Jan;1(1):43-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the novel prognostic markers is E-cadherin; a calcium-dependent epithelial cell adhesion molecule.
  • The median tumor size was 3cms.
  • However, there was no correlation between the E-cadherin and other prognostic parameters as tumor size, tumor grade, ER, PR, and HER-2 expression.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1993 Dec;143(6):1731-42 [8256859.001]
  • [Cites] Mod Pathol. 2003 Nov;16(11):1067-75 [14614045.001]
  • [Cites] Surg Oncol. 2000 Dec;9(4):151-71 [11476987.001]
  • [Cites] EMBO J. 1995 Dec 15;14(24):6107-15 [8557030.001]
  • [Cites] J Pathol. 2001 Apr;193(4):433-41 [11276001.001]
  • [Cites] Saudi Med J. 2001 Feb;22(2):110-3 [11299401.001]
  • [Cites] Saudi Med J. 2000 Sep;21(9):869-72 [11376366.001]
  • [Cites] J Pak Med Assoc. 2001 Jul;51(7):243-7 [11558215.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1958-63 [11747340.001]
  • [Cites] Ann Surg. 2002 Jan;235(1):10-26 [11753038.001]
  • [Cites] Saudi Med J. 2002 Oct;23(10):1210-3 [12436125.001]
  • [Cites] Saudi Med J. 2003 Jun;24(6):623-7 [12847591.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):14-8 [15459769.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):499-508 [16107313.001]
  • [Cites] Indian J Med Sci. 1991 Apr;45(4):85-7 [1660447.001]
  • [Cites] Curr Opin Cell Biol. 1993 Oct;5(5):806-11 [8240824.001]
  • [Cites] Int J Cancer. 1992 Aug 19;52(1):48-51 [1500227.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):987-93 [7682767.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1B):561-7 [9066580.001]
  • (PMID = 21475451.001).
  • [ISSN] 1658-3639
  • [Journal-full-title] International journal of health sciences
  • [ISO-abbreviation] Int J Health Sci (Qassim)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC3068666
  • [Keywords] NOTNLM ; E-cadherin / breast cancer / immunohistochemistry / immunostaining / prognostic factors
  •  go-up   go-down


Advertisement
4. Kuijpers DI, Thissen MR, Thissen CA, Neumann MH: Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. J Drugs Dermatol; 2006 Jul-Aug;5(7):642-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma.
  • BACKGROUND: Photodynamic therapy (PDT) for basal cell carcinoma (BCC) is a treatment modality that is increasingly used in dermato-oncology.
  • RESULTS: Residual tumor tissue was detected in 6 BCCs of each study group.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865869.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


5. Behrendt U, Schumann P, Stieglmeier M, Pukall R, Augustin J, Spröer C, Schwendner P, Moissl-Eichinger C, Ulrich A: Characterization of heterotrophic nitrifying bacteria with respiratory ammonification and denitrification activity--description of Paenibacillus uliginis sp. nov., an inhabitant of fen peat soil and Paenibacillus purispatii sp. nov., isolated from a spacecraft assembly clean room. Syst Appl Microbiol; 2010 Oct;33(6):328-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of heterotrophic nitrifying bacteria with respiratory ammonification and denitrification activity--description of Paenibacillus uliginis sp. nov., an inhabitant of fen peat soil and Paenibacillus purispatii sp. nov., isolated from a spacecraft assembly clean room.
  • In the course of studying the influence of N-fertilization on N(2) and N(2)O flux rates in relation to soil bacterial community composition of a long-term fertilization experiment in fen peat grassland, a strain group was isolated that was related to a strain isolated from a spacecraft assembly clean room during diversity studies of microorganisms, which withstood cleaning and bioburden reduction strategies.
  • Both the fen soil isolates and the clean room strain revealed versatile physiological capacities in N-transformation processes by performing heterotrophic nitrification, respiratory ammonification and denitrification activity.
  • Phylogenetic analysis based on 16S rRNA gene sequences demonstrated that the investigated isolates belonged to the genus Paenibacillus.
  • Sequence similarities lower than 97% in comparison to established species indicated a separate species position.
  • Except for the peptidoglycan type (A4alpha L-Lys-D-Asp), chemotaxonomic features of the isolates matched the genus description, but differences in several physiological characteristics separated them from related species and supported their novel species status.
  • Despite a high 16S rRNA gene sequence similarity between the clean room isolate ES_MS17(T) and the representative fen soil isolate N3/975(T), DNA-DNA hybridization studies revealed genetic differences at the species level.
  • These differences were substantiated by MALDI-TOF MS analysis, ribotyping and several distinct physiological characteristics.
  • On the basis of these results, it was concluded that the fen soil isolates and the clean room isolate ES_MS17(T) represented two novel species for which the names Paenibacillus uliginis sp. nov. (type strain N3/975(T)=DSM 21861(T)=LMG 24790(T)) and Paenibacillus purispatii sp. nov. (type strain ES_MS17(T)=DSM 22991(T)=CIP 110057(T)) are proposed.
  • [MeSH-major] Air Microbiology. Nitrification. Paenibacillus / classification. Paenibacillus / isolation & purification. Soil Microbiology
  • [MeSH-minor] Bacterial Typing Techniques. Cluster Analysis. DNA, Bacterial / chemistry. DNA, Bacterial / genetics. DNA, Ribosomal / chemistry. DNA, Ribosomal / genetics. Denitrification. Environment, Controlled. Molecular Sequence Data. Nucleic Acid Hybridization. Phylogeny. RNA, Ribosomal, 16S / genetics. Sequence Analysis, DNA. Soil. Spacecraft

  • SILVA. SILVA SSU Database .
  • StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20813476.001).
  • [ISSN] 1618-0984
  • [Journal-full-title] Systematic and applied microbiology
  • [ISO-abbreviation] Syst. Appl. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EU888513/ FN556467
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal; 0 / RNA, Ribosomal, 16S; 0 / Soil
  •  go-up   go-down


6. Ma Y, Hu C, Riegel AT, Fan S, Rosen EM: Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity. Mol Endocrinol; 2007 Aug;21(8):1905-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Male. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism


7. Wakai K, Tamakoshi K, Date C, Fukui M, Suzuki S, Lin Y, Niwa Y, Nishio K, Yatsuya H, Kondo T, Tokudome S, Yamamoto A, Toyoshima H, Tamakoshi A, JACC Study Group: Dietary intakes of fat and fatty acids and risk of breast cancer: a prospective study in Japan. Cancer Sci; 2005 Sep;96(9):590-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / epidemiology. Dietary Fats. Fatty Acids / physiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Cancer Sci 2005; 96: 590 - 599).
  • (PMID = 16128744.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Fatty Acids
  •  go-up   go-down


8. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC: The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer; 2005 Jul;12 Suppl 1:S37-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, initial preclinical studies suggest that treatment strategies designed to prevent or interrupt activation of NFkappaB in cell-line models of these more aggressive, ER-positive breast cancers can restore their sensitivity to such standard endocrine agents as tamoxifen.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. NF-kappa B / antagonists & inhibitors
  • [MeSH-minor] Drug Resistance, Neoplasm / drug effects. Female. Humans. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / metabolism. Receptors, Estrogen / antagonists & inhibitors. Receptors, Estrogen / metabolism. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16113098.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50-CA58207; United States / NIA NIH HHS / AG / R01-AG20521; United States / NCI NIH HHS / CA / R01-CA36773; United States / NCI NIH HHS / CA / R01-CA71468
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / NF-kappa B; 0 / Receptors, Estrogen
  • [Number-of-references] 59
  •  go-up   go-down


9. Ishikawa T, Momiyama N, Hamaguchi Y, Tanabe M, Tomita S, Ichikawa Y, Nakatani Y, Sasaki T, Nozawa A, Inayama Y, Inui K, Shimada H: Blue-dye technique complements four-node sampling for early breast cancer. Eur J Surg Oncol; 2005 Dec;31(10):1119-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / pathology. Coloring Agents. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adult. Aged. Axilla. Feasibility Studies. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Surg Oncol. 2007 Jun;33(5):670 [17344016.001]
  • (PMID = 16005597.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coloring Agents
  •  go-up   go-down


10. Anim JT, John B, Abdulsathar S SA, Prasad A, Saji T, Akhtar N, Ali V, Al-Saleh M: Relationship between the expression of various markers and prognostic factors in breast cancer. Acta Histochem; 2005;107(2):87-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The immunohistochemical detection of six markers of breast cancer has been compared in the present study with known prognostic factors of the disease to establish locally a standard panel of markers for the management of breast cancer.
  • Using the chi(2)-test, relationships were determined between marker labelling and histological type of cancer, tumour grade, tumour size, axillary lymph node status and age of patient.
  • All markers showed no significant relationship with size of tumour, presence of axillary node metastasis or age of patient.
  • We found no relationship between the markers and tumour size, axillary lymph node status or age.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / metabolism. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Staging. Prognosis


11. Gottwald D, Likos CN, Kahl G, Löwen H: Ionic microgels as model systems for colloids with an ultrasoft electrosteric repulsion: structure and thermodynamics. J Chem Phys; 2005 Feb 15;122(7):074903
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ionic microgels as model systems for colloids with an ultrasoft electrosteric repulsion: structure and thermodynamics.
  • We present a theoretical analysis of the structural properties and phase behavior of spherical, loosely cross-linked ionic microgels that possess a low monomer concentration.
  • The analysis is based on the recently derived effective interaction potential between such particles [A. R.
  • Denton, Phys. Rev. E 67, 011804 (2003)].
  • By employing standard tools from the theory of the liquid state, we quantitatively analyze the pair correlations in the fluid and find anomalous behavior above the overlap concentration, similar to the cases of star-branched neutral and charged polymers.
  • We also employ an evolutionary algorithm in order to predict the crystalline phases of the system without any a priori assumptions regarding their symmetry class.
  • A very rich phase diagram is obtained, featuring two reentrant melting transitions and a number of unusual crystal structures.
  • At high densities, both the Hansen-Verlet freezing criterion [J.-P. Hansen and L.
  • Verlet, Phys. Rev. 184, 151 (1969)] and the Lindemann melting criterion [F. A.
  • Lindemann, Phys. Z. 11, 609 (1910)] lose their validity.
  • The topology of the phase diagram is altered when the steric interactions between the polymer segments become strong enough, in which case the lower-density reentrant melting disappears and the region of stability of the fluid is split into two disconnected domains, separated by intervening fcc and bcc regions.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15743266.001).
  • [ISSN] 0021-9606
  • [Journal-full-title] The Journal of chemical physics
  • [ISO-abbreviation] J Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Gorey KM, Luginaah IN, Schwartz KL, Fung KY, Balagurusamy M, Bartfay E, Wright FC, Anucha U, Parsons RR: Increased racial differences on breast cancer care and survival in America: historical evidence consistent with a health insurance hypothesis, 1975-2001. Breast Cancer Res Treat; 2009 Feb;113(3):595-600
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This study examined whether race/ethnicity had differential effects on breast cancer care and survival across age strata and cohorts within stages of disease.
  • Within node positive disease all treatment disadvantages among younger African American women disappeared with socioeconomic adjustment.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Health Disparities.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2007 Jun 1;109(11):2161-70 [17455219.001]
  • [Cites] Breast Cancer Res Treat. 2006 May;97(2):149-55 [16322888.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2516-21 [17577028.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2522-7 [17577029.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jun;109(3):545-57 [17659438.001]
  • [Cites] Arch Fam Med. 1999 Nov-Dec;8(6):521-8 [10575392.001]
  • [Cites] Med Care. 2000 Jul;38(7):705-18 [10901354.001]
  • [Cites] Am J Public Health. 2000 Dec;90(12):1866-72 [11111258.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2202-13 [11147590.001]
  • [Cites] J Gen Intern Med. 2001 Mar;16(3):189-99 [11318915.001]
  • [Cites] Am J Public Health. 2002 Jan;92(1):64-70 [11772763.001]
  • [Cites] Am J Epidemiol. 2002 Mar 15;155(6):534-45 [11882527.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):490-6 [11929949.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2106-13 [11966385.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2844-54 [12115371.001]
  • [Cites] Am J Epidemiol. 2002 Sep 1;156(5):471-82 [12196317.001]
  • [Cites] Milbank Q. 2002;80(4):677-707, iv [12532644.001]
  • [Cites] Ann Epidemiol. 2003 Jan;13(1):32-41 [12547483.001]
  • [Cites] Med Care. 2003 Jun;41(6):722-8 [12773838.001]
  • [Cites] J Clin Epidemiol. 2003 Jul;56(7):678-85 [12921937.001]
  • [Cites] Am J Public Health. 2003 Oct;93(10):1655-71 [14534218.001]
  • [Cites] Arch Intern Med. 2003 Oct 13;163(18):2135-44 [14557210.001]
  • [Cites] J Health Care Poor Underserved. 2003 Nov;14(4):503-15 [14619552.001]
  • [Cites] Cancer Causes Control. 2003 Oct;14(8):761-6 [14674740.001]
  • [Cites] Am J Public Health. 2004 Oct;94(10):1795-9 [15451752.001]
  • [Cites] Am J Public Health. 2004 Nov;94(11):1992-7 [15514242.001]
  • [Cites] Med Care Rev. 1989 Winter;46(4):349-85 [10304178.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1297-301 [2400978.001]
  • [Cites] Health Policy. 1991;19(2-3):91-118 [10115996.001]
  • [Cites] Am J Epidemiol. 1992 Mar 15;135(6):609-18 [1580237.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 16;85(12):979-87 [8496983.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):788-98 [8334632.001]
  • [Cites] Am J Public Health. 1994 Jun;84(6):1003-6 [8203664.001]
  • [Cites] JAMA. 1994 Sep 28;272(12):947-54 [8084062.001]
  • [Cites] Med Care Res Rev. 1995 Sep;52(3):389-408 [10144870.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):80-90 [9210712.001]
  • [Cites] Am J Obstet Gynecol. 1997 Jun;176(6):S233-9 [9215214.001]
  • [Cites] Am J Public Health. 1997 Jul;87(7):1156-63 [9240106.001]
  • [Cites] Ann Epidemiol. 2006 Oct;16(10):789-91; author reply 792-3 [16882472.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jan;101(2):207-14 [16838114.001]
  • [Cites] Ethn Dis. 1997 Spring-Summer;7(2):137-49 [9386954.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1310-8 [9529023.001]
  • [Cites] Am J Public Health. 1999 Jan;89(1):36-42 [9987462.001]
  • [Cites] Health Serv Res. 1999 Apr;34(1 Pt 2):271-9 [10199674.001]
  • [Cites] Surgery. 1999 Apr;125(4):375-9 [10216527.001]
  • [Cites] JAMA. 1999 Jul 14;282(2):159-63 [10411197.001]
  • [Cites] Am J Clin Oncol. 1999 Oct;22(5):436-40 [10521053.001]
  • [Cites] Milbank Q. 1999;77(3):401-7 [10526551.001]
  • [Cites] Breast J. 2005 Mar-Apr;11(2):124-8 [15730458.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jun;91(3):243-8 [15952057.001]
  • [Cites] Am J Public Health. 2006 Jan;96(1):160-6 [16317209.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jan;95(1):89-95 [16244785.001]
  • [Cites] Am J Epidemiol. 2007 Jul 1;166(1):71-8 [17426038.001]
  • (PMID = 18330694.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / / 42633-1; Canada / Canadian Institutes of Health Research / / 67161; Canada / Canadian Institutes of Health Research / / 67161-1; Canada / Canadian Institutes of Health Research / / 42633; None / None / / 42633-1; None / None / / 42633; None / None / / N01 PC065064; None / None / / 67161-1; None / None / / 67161; United States / NCI NIH HHS / PC / N01-PC 65064
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ CAMS1396; NLM/ PMC2909273
  •  go-up   go-down


13. Pant K, Dutta U: Understanding and management of male breast cancer: a critical review. Med Oncol; 2008;25(3):294-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast cancer is a rare disease in men representing nearly 1% of the total breast cancer cases worldwide.
  • While treatments developed for women with breast cancer are often applied to treat men with breast cancer, however, lack of awareness of this disease leads to its detection at a later stage in men.
  • This review discusses male breast cancer and draws comparisons with female breast cancer and discusses current treatments available to treat this disease.
  • [MeSH-major] Breast Neoplasms / therapy. Breast Neoplasms, Male / epidemiology. Breast Neoplasms, Male / therapy
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Aromatase Inhibitors / therapeutic use. Chemotherapy, Adjuvant. Estrogens / metabolism. Female. Humans. Male. Neoplasm Staging. Sex Characteristics. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):70-4 [8989235.001]
  • [Cites] Eur J Cancer. 1995 Nov;31A(12):1960-4 [8562148.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):629-39 [10091736.001]
  • [Cites] J Clin Endocrinol Metab. 1974 Mar;38(3):476-9 [4815174.001]
  • [Cites] Int J Oncol. 2004 Mar;24(3):663-70 [14767551.001]
  • [Cites] Nat Genet. 1994 May;7(1):103-7 [8075631.001]
  • [Cites] Endocrinology. 1996 Dec;137(12):5739-42 [8940410.001]
  • [Cites] Br J Cancer. 1985 Jan;51(1):115-9 [3966965.001]
  • [Cites] Am J Hum Genet. 2001 Feb;68(2):410-9 [11170890.001]
  • [Cites] Cancer. 1989 Oct 15;64(8):1583-5 [2676137.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):490-8 [8630956.001]
  • [Cites] Endocrinology. 1985 Jan;116(1):38-46 [2981072.001]
  • [Cites] Endocr Relat Cancer. 1999 Jun;6(2):131-7 [10731101.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2750-6 [16782915.001]
  • [Cites] Endocrinology. 1997 Dec;138(12):5125-35 [9389492.001]
  • [Cites] Bull Cancer. 2005 Mar;92(3):281-5 [15820923.001]
  • [Cites] Am J Clin Oncol. 1987 Feb;10(1):55-60 [3825994.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):225-30 [14623515.001]
  • [Cites] Eur J Cancer. 1998 Aug;34(9):1341-7 [9849414.001]
  • [Cites] Expert Opin Pharmacother. 2007 Feb;8(2):193-202 [17257089.001]
  • [Cites] J Health Psychol. 2002 May;7(3):209-17 [22114245.001]
  • [Cites] Med Oncol. 2008;25(2):113-24 [17973095.001]
  • [Cites] Ann Intern Med. 2002 Oct 15;137(8):678-87 [12379069.001]
  • [Cites] Mol Cell Endocrinol. 1998 Apr 30;139(1-2):117-29 [9705080.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):446-9 [8621225.001]
  • [Cites] BMJ. 2001 Nov 3;323(7320):1055-8 [11691767.001]
  • [Cites] Eur J Cancer. 2006 Feb;42(3):334-41 [16377181.001]
  • [Cites] Cancer Treat Rev. 2006 Apr;32(2):101-5 [16472925.001]
  • [Cites] Cancer Detect Prev. 2006;30(6):530-4 [17113724.001]
  • [Cites] Recent Prog Horm Res. 1997;52:185-213; discussion 213-4 [9238853.001]
  • [Cites] Gynecol Obstet Fertil. 2006 May;34(5):413-9 [16630739.001]
  • [Cites] BMJ. 1998 Oct 17;317(7165):1072-5 [9774301.001]
  • [Cites] Endocrinology. 1993 Mar;132(3):1396-401 [8440194.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):39-44 [16434584.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):51-7 [15221988.001]
  • [Cites] Oncologist. 2005 Aug;10(7):471-9 [16079314.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2359-64 [16270318.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Breast Cancer Res Treat. 2007 May;103(1):11-21 [17033919.001]
  • [Cites] J Endocrinol. 2000 Feb;164(2):225-38 [10657858.001]
  • [Cites] Lancet. 2006 Feb 18;367(9510):595-604 [16488803.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2109-11 [9187104.001]
  • (PMID = 18074245.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Estrogens; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 43
  •  go-up   go-down


14. Surrenti T, De Angelis L, Di Cesare A, Fargnoli MC, Peris K: Efficacy of photodynamic therapy with methyl aminolevulinate in the treatment of superficial and nodular basal cell carcinoma: an open-label trial. Eur J Dermatol; 2007 Sep-Oct;17(5):412-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of photodynamic therapy with methyl aminolevulinate in the treatment of superficial and nodular basal cell carcinoma: an open-label trial.
  • Photodynamic therapy with methyl aminolevulinate (MAL-PDT) is a non-invasive therapy for superficial and nodular basal cell carcinoma (BCC).
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673385.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


15. Vucetić B, Rogan SA, Hrabac P, Hudorović N, Cupić H, Lukinac L, Ledinsky M, Matejcić A, Lovricević I, Zekan M: Biological value of melanoma inhibitory activity serum concentration in patients with primary skin melanoma. Melanoma Res; 2008 Jun;18(3):201-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanoma inhibitory activity (MIA) protein was identified in significant quantities in primary and metastatic malignant melanomas, where it has an important role in promoting tumor development and progression.
  • Our hypothesis was that MIA serum level will be elevated in patients with metastases or local spreading of the disease before any symptom of such progression is clinically apparent.
  • In addition, MIA serum levels were studied in two control groups; patients with dysplastic nevi and patients with basal cell carcinoma.
  • Patients with histologically positive sentinel lymph nodes, meaning that tumor cells were found in the lymph nodes, had much higher mean MIA values than any other patient group considered in this study.
  • In our opinion, MIA serum level is the ideal test for screening the tumor spread to sentinel lymph nodes.
  • [MeSH-major] Extracellular Matrix Proteins / blood. Melanoma / blood. Melanoma / diagnosis. Neoplasm Proteins / blood. Skin Neoplasms / blood. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / blood. Carcinoma, Basal Cell / blood. Carcinoma, Basal Cell / pathology. Dysplastic Nevus Syndrome / blood. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Predictive Value of Tests. Prognosis. Reference Values. Sensitivity and Specificity. Sentinel Lymph Node Biopsy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477894.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins; 0 / MIA protein, human; 0 / Neoplasm Proteins
  •  go-up   go-down


16. Brinckmann S, Kim JY, Greer JR: Fundamental differences in mechanical behavior between two types of crystals at the nanoscale. Phys Rev Lett; 2008 Apr 18;100(15):155502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fundamental differences in mechanical behavior between two types of crystals at the nanoscale.
  • We present differences in the mechanical behavior of nanoscale gold and molybdenum single crystals.
  • A significant strength increase is observed as the size is reduced to 100 nm.
  • Both nanocrystals exhibit discrete strain bursts during plastic deformation.
  • We postulate that they arise from significant differences in the dislocation behavior.
  • Dislocation starvation is the predominant mechanism of plasticity in nanoscale fcc crystals, while junction formation and hardening characterize bcc plasticity.
  • A statistical analysis of strain bursts is performed as a function of size and compared with stochastic models.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18518121.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol; 2009 Mar 10;27(8):1160-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE To improve on current standards for breast cancer prognosis and prediction of chemotherapy benefit by developing a risk model that incorporates the gene expression-based "intrinsic" subtypes luminal A, luminal B, HER2-enriched, and basal-like.
  • RESULTS: The intrinsic subtypes as discrete entities showed prognostic significance (P = 2.26E-12) and remained significant in multivariable analyses that incorporated standard parameters (estrogen receptor status, histologic grade, tumor size, and node status).
  • The C-index estimate for the combined model (subtype and tumor size) was a significant improvement on either the clinicopathologic model or subtype model alone.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8331-9 [16293864.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Genome Biol. 2002 Jun 25;3(7):RESEARCH0036 [12184810.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Methods Mol Biol. 2003;224:149-57 [12710672.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):671-9 [15721472.001]
  • [Cites] J Clin Oncol. 2005 Mar 10;23(8):1631-5 [15755970.001]
  • [Cites] Bioinformatics. 2005 Nov 15;21(22):4148-54 [16174683.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):262-72 [16478745.001]
  • [Cites] BMC Genomics. 2006;7:96 [16643655.001]
  • [Cites] Breast Cancer Res. 2006;8(2):R23 [16626501.001]
  • [Cites] J Clin Oncol. 2006 Aug 10;24(23):3726-34 [16720680.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):560-9 [16899776.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10292-301 [17079448.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1198-207 [17317830.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1239-46 [17401012.001]
  • [Cites] Clin Chem. 2007 Jul;53(7):1273-9 [17525107.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4236-44 [16896004.001]
  • [CommentIn] J Clin Oncol. 2009 Mar 10;27(8):1153-4 [19204193.001]
  • (PMID = 19204204.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114722-01; United States / NCI NIH HHS / CA / P30 CA42014-19; United States / NCI NIH HHS / CA / P50-CA58223-09A1; United States / NCI NIH HHS / CA / U01 CA114722; United States / NCI NIH HHS / CA / P30 CA91842; United States / NCI NIH HHS / CA / P50 CA058223; United States / NCI NIH HHS / CA / P30 CA091842; United States / NCATS NIH HHS / TR / UL1 TR000448; United States / NCI NIH HHS / CA / P30 CA042014
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2667820
  •  go-up   go-down


18. Mariolis-Sapsakos T, Theodoropoulos G, Flessas II, Orfanos F, Orfanos N, Konstantinou EA, Zagouri F, Vlachodimitropoulos D, Zografos GC: Lobular breast cancer in men: case report and review of the literature. Onkologie; 2010;33(12):698-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms, Male / diagnosis. Carcinoma, Lobular / diagnosis
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Breast / pathology. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Karyotyping. Male. Mastectomy, Modified Radical. Neoplasm Invasiveness. Neoplasm Staging


19. Della Puppa A, Dal Pos S, Zovato S, Orvieto E, Ciccarino P, Manara R, Zustovich F, Berti F, Gardiman MP, Scienza R: Solitary intra-ventricular brain metastasis from a breast carcinoma. J Neurooncol; 2010 Mar;97(1):123-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brain Neoplasms / secondary. Breast Neoplasms / pathology. Carcinoma / pathology. Lateral Ventricles / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] No Shinkei Geka. 1999 Apr;27(4):359-63 [10347852.001]
  • [Cites] J Neurooncol. 1999;45(3):237-40 [10845394.001]
  • [Cites] South Med J. 1998 Dec;91(12 ):1159-62 [9853731.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1475-8 [15956518.001]
  • [Cites] Neurol Med Chir (Tokyo). 1997 Dec;37(12 ):916-9 [9465591.001]
  • [Cites] Neurol India. 2008 Apr-Jun;56(2):179-81 [18688144.001]
  • [Cites] Magn Reson Med Sci. 2003 Oct 1;2(3):155-8 [16222108.001]
  • [Cites] J Clin Neurosci. 2004 Jun;11(5):521-3 [15177398.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):506 [10701550.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):157-60 [15690132.001]
  • [Cites] J Neurooncol. 1996 Jan;27(1):47-52 [8699225.001]
  • [Cites] J Clin Neurosci. 2008 May;15(5):594-7 [18313927.001]
  • (PMID = 19727563.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Cheng NX, Liu LG, Hui L, Chen YL, Xu SL: Breast cancer following augmentation mammaplasty with polyacrylamide hydrogel (PAAG) injection. Aesthetic Plast Surg; 2009 Jul;33(4):563-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The delayed diagnosis and more aggressive disease due to PAAG injection should be cause for concern.
  • [MeSH-major] Acrylic Resins / administration & dosage. Acrylic Resins / adverse effects. Breast Neoplasms / chemically induced. Gels / administration & dosage. Gels / adverse effects. Mammaplasty / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19156460.001).
  • [ISSN] 1432-5241
  • [Journal-full-title] Aesthetic plastic surgery
  • [ISO-abbreviation] Aesthetic Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylic Resins; 0 / Gels; 0 / polyacrylamide gels
  •  go-up   go-down


21. Amnuaykanjanasin A, Punya J, Paungmoung P, Rungrod A, Tachaleat A, Pongpattanakitshote S, Cheevadhanarak S, Tanticharoen M: Diversity of type I polyketide synthase genes in the wood-decay fungus Xylaria sp. BCC 1067. FEMS Microbiol Lett; 2005 Oct 1;251(1):125-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The finding of 11 distinct PKS genes solely by means of PCR cloning supports that PKS genes are highly diverse in fungi.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] FEMS Microbiol Lett. 2006 Jan;254(2):333
  • (PMID = 16112817.001).
  • [ISSN] 0378-1097
  • [Journal-full-title] FEMS microbiology letters
  • [ISO-abbreviation] FEMS Microbiol. Lett.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AF395534/ AY445825/ AY965071/ AY971512/ AY971872/ DQ003485/ DQ011042/ DQ011043/ DQ011045/ DQ011595/ DQ011596
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Fungal; 0 / Fungal Proteins; 79956-01-7 / Polyketide Synthases
  •  go-up   go-down


22. Hansson A, Marín YE, Suh J, Rabson AB, Chen S, Huberman E, Chang RL, Conney AH, Zheng X: Enhancement of TPA-induced growth inhibition and apoptosis in myeloid leukemia cells by BAY 11-7082, an NF-kappaB inhibitor. Int J Oncol; 2005 Oct;27(4):941-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we investigated the role of the transcription factor NF-kappaB in TPA-induced growth inhibition and apoptosis in the myeloid leukemia HL-60 cell line and its TPA-resistant cell variant HL-525.
  • Unlike the parental cell line, HL-525 cells are protein kinase C (PKC)-beta deficient and resistant to TPA-induced differentiation and apoptosis.
  • Although the basal level of NF-kappaB activity was low in HL-60 cells, TPA-resistant HL-525 cells had a high basal level of NF-kappaB activity.
  • [MeSH-major] Apoptosis. Cell Proliferation / drug effects. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Leukemia, Myeloid / drug therapy. NF-kappa B / antagonists & inhibitors. Nitriles / pharmacology. Sulfones / pharmacology. Tetradecanoylphorbol Acetate / pharmacology
  • [MeSH-minor] Active Transport, Cell Nucleus. Cell Adhesion. Cell Differentiation. Cell Line, Tumor. Cell Nucleus / metabolism. Cell Survival. DNA / chemistry. DNA Damage. Dose-Response Relationship, Drug. HL-60 Cells. Humans. I-kappa B Proteins / metabolism. Immunophenotyping. Phosphorylation. Propidium / pharmacology. Protein Kinase C / metabolism. Protein Kinase C beta. Time Factors

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142309.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 092268; United States / NCI NIH HHS / CA / CA 80826
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 3-(4-methylphenylsulfonyl)-2-propenenitrile; 0 / I-kappa B Proteins; 0 / NF-kappa B; 0 / Nitriles; 0 / Sulfones; 139874-52-5 / NF-kappaB inhibitor alpha; 36015-30-2 / Propidium; 9007-49-2 / DNA; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C beta; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


23. Yemelyanov A, Gasparian A, Lindholm P, Dang L, Pierce JW, Kisseljov F, Karseladze A, Budunova I: Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene; 2006 Jan 19;25(3):387-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A key antiapoptotic transcription factor, nuclear factor kappa-B (NF-kappaB), is known to be critically important for tumor cell growth, angiogenesis and development of metastatic lesions.
  • We and others showed previously that NF-kappaB transcription factor was constitutively activated in androgen-independent prostate carcinoma (PC) cell lines due to the upregulated activity of inhibitor of NF-kappaB kinases (IKK).
  • In this work, using luciferase assay, electrophoretic mobility shift assay and Northern blot analysis of expression of endogenous kappaB-responsive genes, we demonstrate that a novel highly specific small-molecule IKK inhibitor, PS1145, efficiently inhibited both basal and induced NF-kappaB activity in PC cells.
  • We found that PS1145 induced caspase 3/7-dependent apoptosis in PC cells and significantly sensitized PC cells to apoptosis induced by tumor necrosis factor alpha.
  • We also showed that PS1145 inhibited PC cell proliferation.
  • [MeSH-major] Apoptosis / drug effects. Cell Proliferation / drug effects. Enzyme Inhibitors / pharmacology. Heterocyclic Compounds, 3-Ring / pharmacology. I-kappa B Kinase / antagonists & inhibitors. NF-kappa B / physiology. Neoplasm Invasiveness / prevention & control. Prostatic Neoplasms / pathology. Pyridines / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Male. Phosphorylation. Rats. Signal Transduction


24. Calaluce R, Beck SK, Bair EL, Pandey R, Greer KA, Hoying AM, Hoying JB, Mount DW, Nagle RB: Human laminin-5 and laminin-10 mediated gene expression of prostate carcinoma cells. Prostate; 2006 Sep 15;66(13):1381-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In prostate cancer progression, the basal lamina switches from predominantly laminin-5 to laminin-10.
  • EGFR was validated by real-time PCR and laminin-10 mediated cell adhesion activated EGFR in DU-145 cells.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16804886.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA056666; United States / NCI NIH HHS / CA / 2 P01 CA56666-08A1; United States / NCI NIH HHS / CA / K08 CA90662-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / DNA, Neoplasm; 0 / Laminin; 0 / RNA, Neoplasm; 0 / kalinin; 0 / laminin 10; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.4.22.- / Calpain
  •  go-up   go-down


25. Davidchack RL, Laird BB: Crystal structure and interaction dependence of the crystal-melt interfacial free energy. Phys Rev Lett; 2005 Mar 4;94(8):086102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crystal structure and interaction dependence of the crystal-melt interfacial free energy.
  • We examine via molecular simulation the dependence of the crystal-melt interfacial free energy gamma on molecular interaction and crystal structure (fcc vs bcc) for systems interacting with inverse-power repulsive potentials, u(r)=epsilon(sigma/r)(n), 6< or =n< or =100.
  • Both the magnitude and anisotropy of gamma are found to increase as the range of the potential increases.
  • Also we find that gamma(bcc)<gamma(fcc), consistent with recent observations that some fcc forming fluids nucleate via formation of metastable bcc nuclei.
  • The anisotropy in gamma is also seen to be smaller in the bcc systems.
  • By extrapolation, we also obtain an improved estimate of gamma for hard spheres.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783906.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Katase N, Nagatsuka H, Tsujigiwa H, Gunduz M, Tamamura R, Pwint HP, Rivera RS, Nakajima M, Naomoto Y, Nagai N: Analysis of the neoplastic nature and biological potential of sporadic and nevoid basal cell carcinoma syndrome-associated keratocystic odontogenic tumor. J Oral Pathol Med; 2007 Oct;36(9):550-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the neoplastic nature and biological potential of sporadic and nevoid basal cell carcinoma syndrome-associated keratocystic odontogenic tumor.
  • BACKGROUND: Keratocystic odontogenic tumor (KCOT), also known as odontogenic keratocyst, is a benign cystic neoplasm, which may be associated with nevoid basal cell carcinoma syndrome (NBCCS) and if it does, will occur as multiple cystic lesions.
  • [MeSH-major] Basal Cell Nevus Syndrome / enzymology. Glucuronidase / biosynthesis. Odontogenic Cysts / enzymology. Odontogenic Tumors / enzymology
  • [MeSH-minor] Dentigerous Cyst / enzymology. Gene Expression Regulation, Neoplastic. Heparan Sulfate Proteoglycans / metabolism. Humans. Immunohistochemistry. In Situ Hybridization. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17850439.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Heparan Sulfate Proteoglycans; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


27. Kwon S, Kim TS, Yu GH, Jung JH, Park HD: Bacterial community composition and diversity of a full-scale integrated fixed-film activated sludge system as investigated by pyrosequencing. J Microbiol Biotechnol; 2010 Dec;20(12):1717-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bacterial community composition and diversity of a full-scale integrated fixed-film activated sludge system as investigated by pyrosequencing.
  • The integrated fixed-film activated sludge (IFAS) system is a variation of the activated sludge wastewater treatment process, in which hybrid suspended and attached biomass is used to treat wastewater.
  • Although the function and performance of the IFAS system are well studied, little is known about its microbial community structure.
  • In this study, the composition and diversity of the bacterial community of suspended and attached biomass samples were investigated in a full-scale IFAS system using a highthroughput pyrosequencing technology.
  • Distinct bacterial community compositions were examined for each sample and appeared to be important for its features different from conventional activated sludge processes.
  • The abundant bacterial groups were Betaproteobacteria (59.3%), Gammaproteobacteria (8.1%), Bacteroidetes (5.2%), Alphaproteobacteria (3.9%), and Actinobacteria (3.2%) in the suspended sample, whereas Actinobacteria (14.6%), Firmicutes (13.6%), Bacteroidetes (11.6%), Betaproteobacteria (9.9%), Gammaproteobacteria (9.25%), and Alphaproteobacteria (7.4%) were major bacterial groups in the attached sample.
  • Regarding the diversity, totals of 3,034 and 1,451 operational taxonomic units were identified at the 3% cutoff for the suspended and attached samples, respectively.
  • Rank abundance and community analyses demonstrated that most of the diversity was originated from rare species in the samples.
  • Taken together, the information obtained in this study will be a base for further studies relating to the microbial community structure and function of the IFAS system.
  • [MeSH-major] Bacteria / classification. Bacteria / genetics. Biodiversity. Sewage / microbiology
  • [MeSH-minor] Cluster Analysis. DNA, Bacterial / chemistry. DNA, Bacterial / genetics. DNA, Ribosomal / chemistry. DNA, Ribosomal / genetics. Molecular Sequence Data. Phylogeny. RNA, Ribosomal, 16S / genetics. Sequence Analysis, DNA. Water Purification

  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21193829.001).
  • [ISSN] 1738-8872
  • [Journal-full-title] Journal of microbiology and biotechnology
  • [ISO-abbreviation] J. Microbiol. Biotechnol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ GU539392/ GU539393/ GU539394/ GU539395/ GU539396/ GU539397/ GU539398/ GU539399/ GU539400/ GU539401/ GU539402/ GU539403/ GU539404/ GU539405/ GU539406/ GU539407/ GU539408/ GU539409/ GU539410/ GU539411/ GU539412/ GU539413/ GU539414/ GU539415/ GU539416/ GU539417/ GU539418/ GU539419/ GU539420/ GU539421/ GU539422/ GU539423/ GU539424/ GU539425/ GU539426/ GU539427/ GU539428/ GU539429/ GU539430/ GU539431/ GU539432/ GU539433/ GU539434/ GU539435/ GU539436/ GU539437/ GU539438/ GU539439/ GU539440/ GU539441/ GU539442/ GU539443/ GU539444/ GU539445/ GU539446/ GU539447/ GU539448/ GU539449/ GU539450/ GU539451/ GU539452/ GU539453/ GU539454/ GU539455/ GU539456/ GU539457/ GU539458/ GU539459/ GU539460/ GU539461/ GU539462/ GU539463/ GU539464/ GU539465/ GU539466/ GU539467/ GU539468/ GU539469/ GU539470/ GU539471/ GU539472/ GU539473/ GU539474/ GU539475/ GU539476/ GU539477/ GU539478/ GU539479/ GU539480/ GU539481/ GU539482/ GU539483/ GU539484/ GU539485/ GU539486/ GU539487/ GU539488/ GU539489/ GU539490/ GU539491/ GU539492/ GU539493/ GU539494/ GU539495/ GU539496/ GU539497/ GU539498/ GU539499/ GU539500/ GU539501/ GU539502/ GU539503/ GU539504/ GU539505/ GU539506/ GU539507/ GU539508/ GU539509/ GU539510/ GU539511/ GU539512/ GU539513/ GU539514/ GU539515/ GU539516/ GU539517/ GU539518/ GU539519/ GU539520/ GU539521/ GU539522/ GU539523/ GU539524/ GU539525/ GU539526/ GU539527/ GU539528/ GU539529/ GU539530/ GU539531/ GU539532/ GU539533/ GU539534/ GU539535/ GU539536/ GU539537/ GU539538/ GU539539/ GU539540/ GU539541/ GU539542/ GU539543/ GU539544/ GU539545/ GU539546/ GU539547/ GU539548/ GU539549/ GU539550/ GU539551/ GU539552/ GU539553/ GU539554/ GU539555/ GU539556/ GU539557/ GU539558/ GU539559/ GU539560/ GU539561/ GU539562/ GU539563/ GU539564/ GU539565/ GU539566/ GU539567/ GU539568/ GU539569/ GU539570/ GU539571/ GU539572/ GU539573/ GU539574/ GU539575/ GU539576/ GU539577/ GU539578/ GU539579/ GU539580/ GU539581/ GU539582/ GU539583/ GU539584/ GU539585/ GU539586/ GU539587/ GU539588/ GU539589/ GU539590/ GU539591/ GU539592/ GU539593/ GU539594/ GU539595/ GU539596/ GU539597/ GU539598/ GU539599/ GU539600/ GU539601/ GU539602/ GU539603/ GU539604/ GU539605/ GU539606/ GU539607/ GU539608/ GU539609/ GU539610/ GU539611/ GU539612/ GU539613/ GU539614/ GU539615/ GU539616/ GU539617/ GU539618/ GU539619/ GU539620/ GU539621/ GU539622/ GU539623/ GU539624/ GU539625/ GU539626/ GU539627/ GU539628/ GU539629/ GU539630/ GU539631/ GU539632/ GU539633/ GU539634/ GU539635/ GU539636/ GU539637/ GU539638/ GU539639/ GU539640/ GU539641/ GU539642/ GU539643/ GU539644/ GU539645/ GU539646/ GU539647/ GU539648/ GU539649/ GU539650/ GU539651/ GU539652/ GU539653/ GU539654/ GU539655/ GU539656/ GU539657/ GU539658/ GU539659/ GU539660/ GU539661/ GU539662/ GU539663/ GU539664/ GU539665/ GU539666/ GU539667/ GU539668/ GU539669/ GU539670/ GU539671/ GU539672/ GU539673/ GU539674/ GU539675/ GU539676/ GU539677/ GU539678/ GU539679/ GU539680/ GU539681/ GU539682/ GU539683/ GU539684/ GU539685/ GU539686/ GU539687/ GU539688/ GU539689/ GU539690/ GU539691/ GU539692/ GU539693/ GU539694/ GU539695/ GU539696/ GU539697/ GU539698/ GU539699/ GU539700/ GU539701/ GU539702/ GU539703/ GU539704/ GU539705/ GU539706/ GU539707/ GU539708/ GU539709/ GU539710/ GU539711/ GU539712/ GU539713/ GU539714/ GU539715/ GU539716/ GU539717/ GU539718/ GU539719/ GU539720/ GU539721/ GU539722/ GU539723/ GU539724/ GU539725/ GU539726/ GU539727/ GU539728/ GU539729/ GU539730/ GU539731/ GU539732/ GU539733/ GU539734/ GU539735/ GU539736/ GU539737/ GU539738/ GU539739/ GU539740/ GU539741/ GU539742/ GU539743/ GU539744/ GU539745/ GU539746/ GU539747/ GU539748/ GU539749/ GU539750/ GU539751/ GU539752/ GU539753/ GU539754/ GU539755/ GU539756/ GU539757/ GU539758/ GU539759/ GU539760/ GU539761/ GU539762/ GU539763/ GU539764/ GU539765/ GU539766/ GU539767/ GU539768/ GU539769/ GU539770/ GU539771/ GU539772/ GU539773/ GU539774/ GU539775/ GU539776/ GU539777/ GU539778/ GU539779/ GU539780/ GU539781/ GU539782/ GU539783/ GU539784/ GU539785/ GU539786/ GU539787/ GU539788/ GU539789/ GU539790/ GU539791/ GU539792/ GU539793/ GU539794/ GU539795/ GU539796/ GU539797/ GU539798/ GU539799/ GU539800/ GU539801/ GU539802/ GU539803/ GU539804/ GU539805/ GU539806/ GU539807/ GU539808/ GU539809/ GU539810/ GU539811/ GU539812/ GU539813/ GU539814/ GU539815/ GU539816/ GU539817/ GU539818/ GU539819/ GU539820/ GU539821/ GU539822/ GU539823/ GU539824/ GU539825/ GU539826/ GU539827/ GU539828/ GU539829/ GU539830/ GU539831/ GU539832/ GU539833/ GU539834/ GU539835/ GU539836/ GU539837/ GU539838/ GU539839/ GU539840/ GU539841/ GU539842/ GU539843/ GU539844/ GU539845/ GU539846/ GU539847/ GU539848/ GU539849/ GU539850/ GU539851/ GU539852/ GU539853/ GU539854/ GU539855/ GU539856/ GU539857/ GU539858/ GU539859/ GU539860/ GU539861/ GU539862/ GU539863/ GU539864/ GU539865/ GU539866/ GU539867/ GU539868/ GU539869/ GU539870/ GU539871/ GU539872/ GU539873/ GU539874/ GU539875/ GU539876/ GU539877/ GU539878/ GU539879/ GU539880/ GU539881/ GU539882/ GU539883/ GU539884/ GU539885/ GU539886/ GU539887/ GU539888/ GU539889/ GU539890/ GU539891/ GU539892/ GU539893/ GU539894/ GU539895/ GU539896/ GU539897/ GU539898/ GU539899/ GU539900/ GU539901/ GU539902/ GU539903/ GU539904/ GU539905/ GU539906/ GU539907/ GU539908/ GU539909/ GU539910/ GU539911/ GU539912/ GU539913/ GU539914/ GU539915/ GU539916/ GU539917/ GU539918/ GU539919/ GU539920/ GU539921/ GU539922/ GU539923/ GU539924/ GU539925/ GU539926/ GU539927/ GU539928/ GU539929/ GU539930/ GU539931/ GU539932/ GU539933/ GU539934/ GU539935/ GU539936/ GU539937/ GU539938/ GU539939/ GU539940/ GU539941/ GU539942/ GU539943/ GU539944/ GU539945/ GU539946/ GU539947/ GU539948/ GU539949/ GU539950/ GU539951/ GU539952/ GU539953/ GU539954/ GU539955/ GU539956/ GU539957/ GU539958/ GU539959/ GU539960/ GU539961/ GU539962/ GU539963/ GU539964/ GU539965/ GU539966/ GU539967/ GU539968/ GU539969/ GU539970/ GU539971/ GU539972/ GU539973/ GU539974/ GU539975/ GU539976/ GU539977/ GU539978/ GU539979/ GU539980/ GU539981/ GU539982/ GU539983/ GU539984/ GU539985/ GU539986/ GU539987/ GU539988/ GU539989/ GU539990/ GU539991/ GU539992/ GU539993/ GU539994/ GU539995/ GU539996/ GU539997/ GU539998/ GU539999/ GU540000/ GU540001/ GU540002/ GU540003/ GU540004/ GU540005/ GU540006/ GU540007/ GU540008/ GU540009/ GU540010/ GU540011/ GU540012/ GU540013/ GU540014/ GU540015/ GU540016/ GU540017/ GU540018/ GU540019/ GU540020/ GU540021/ GU540022/ GU540023/ GU540024/ GU540025/ GU540026/ GU540027/ GU540028/ GU540029/ GU540030/ GU540031/ GU540032/ GU540033/ GU540034/ GU540035/ GU540036/ GU540037/ GU540038/ GU540039/ GU540040/ GU540041/ GU540042/ GU540043/ GU540044/ GU540045/ GU540046/ GU540047/ GU540048/ GU540049/ GU540050/ GU540051/ GU540052/ GU540053/ GU540054/ GU540055/ GU540056/ GU540057/ GU540058/ GU540059/ GU540060/ GU540061/ GU540062/ GU540063/ GU540064/ GU540065/ GU540066/ GU540067/ GU540068/ GU540069/ GU540070/ GU540071/ GU540072/ GU540073/ GU540074/ GU540075/ GU540076/ GU540077/ GU540078/ GU540079/ GU540080/ GU540081/ GU540082/ GU540083/ GU540084/ GU540085/ GU540086/ GU540087/ GU540088/ GU540089/ GU540090/ GU540091/ GU540092/ GU540093/ GU540094/ GU540095/ GU540096/ GU540097/ GU540098/ GU540099/ GU540100/ GU540101/ GU540102/ GU540103/ GU540104/ GU540105/ GU540106/ GU540107/ GU540108/ GU540109/ GU540110/ GU540111/ GU540112/ GU540113/ GU540114/ GU540115/ GU540116/ GU540117/ GU540118/ GU540119/ GU540120/ GU540121/ GU540122/ GU540123/ GU540124/ GU540125/ GU540126/ GU540127/ GU540128/ GU540129/ GU540130/ GU540131/ GU540132/ GU540133/ GU540134/ GU540135/ GU540136/ GU540137/ GU540138/ GU540139/ GU540140/ GU540141/ GU540142/ GU540143/ GU540144/ GU540145/ GU540146/ GU540147/ GU540148/ GU540149/ GU540150/ GU540151/ GU540152/ GU540153/ GU540154/ GU540155/ GU540156/ GU540157/ GU540158/ GU540159/ GU540160/ GU540161/ GU540162/ GU540163/ GU540164/ GU540165/ GU540166/ GU540167/ GU540168/ GU540169/ GU540170/ GU540171/ GU540172/ GU540173/ GU540174/ GU540175/ GU540176/ GU540177/ GU540178/ GU540179/ GU540180/ GU540181/ GU540182/ GU540183/ GU540184/ GU540185/ GU540186/ GU540187/ GU540188/ GU540189/ GU540190/ GU540191/ GU540192/ GU540193/ GU540194/ GU540195/ GU540196/ GU540197/ GU540198/ GU540199/ GU540200/ GU540201/ GU540202/ GU540203/ GU540204/ GU540205/ GU540206/ GU540207/ GU540208/ GU540209/ GU540210/ GU540211/ GU540212/ GU540213/ GU540214/ GU540215/ GU540216/ GU540217/ GU540218/ GU540219/ GU540220/ GU540221/ GU540222/ GU540223/ GU540224/ GU540225/ GU540226/ GU540227/ GU540228/ GU540229/ GU540230/ GU540231/ GU540232/ GU540233/ GU540234/ GU540235/ GU540236/ GU540237/ GU540238/ GU540239/ GU540240/ GU540241/ GU540242/ GU540243/ GU540244/ GU540245/ GU540246/ GU540247/ GU540248/ GU540249/ GU540250/ GU540251/ GU540252/ GU540253/ GU540254/ GU540255/ GU540256/ GU540257/ GU540258/ GU540259/ GU540260/ GU540261/ GU540262/ GU540263/ GU540264/ GU540265/ GU540266/ GU540267/ GU540268/ GU540269/ GU540270/ GU540271/ GU540272/ GU540273/ GU540274/ GU540275/ GU540276/ GU540277/ GU540278/ GU540279/ GU540280/ GU540281/ GU540282/ GU540283/ GU540284/ GU540285/ GU540286/ GU540287/ GU540288/ GU540289/ GU540290/ GU540291/ GU540292/ GU540293/ GU540294/ GU540295/ GU540296/ GU540297/ GU540298/ GU540299/ GU540300/ GU540301/ GU540302/ GU540303/ GU540304/ GU540305/ GU540306/ GU540307/ GU540308/ GU540309/ GU540310/ GU540311/ GU540312/ GU540313/ GU540314/ GU540315/ GU540316/ GU540317/ GU540318/ GU540319/ GU540320/ GU540321/ GU540322/ GU540323/ GU540324/ GU540325/ GU540326/ GU540327/ GU540328/ GU540329/ GU540330/ GU540331/ GU540332/ GU540333/ GU540334/ GU540335/ GU540336/ GU540337/ GU540338/ GU540339/ GU540340/ GU540341/ GU540342/ GU540343/ GU540344/ GU540345/ GU540346/ GU540347/ GU540348/ GU540349/ GU540350/ GU540351/ GU540352/ GU540353/ GU540354/ GU540355/ GU540356/ GU540357/ GU540358/ GU540359/ GU540360/ GU540361/ GU540362/ GU540363/ GU540364/ GU540365/ GU540366/ GU540367/ GU540368/ GU540369/ GU540370/ GU540371/ GU540372/ GU540373/ GU540374/ GU540375/ GU540376/ GU540377/ GU540378/ GU540379/ GU540380/ GU540381/ GU540382/ GU540383/ GU540384/ GU540385/ GU540386/ GU540387/ GU540388/ GU540389/ GU540390/ GU540391
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal; 0 / RNA, Ribosomal, 16S; 0 / Sewage
  •  go-up   go-down


28. Zedek DC, Langel DJ, White WL: Clear-cell acanthoma versus acanthosis: a psoriasiform reaction pattern lacking tricholemmal differentiation. Am J Dermatopathol; 2007 Aug;29(4):378-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear-cell acanthoma versus acanthosis: a psoriasiform reaction pattern lacking tricholemmal differentiation.
  • Clear-cell acanthoma (CCA) has been reported to be a benign epidermal neoplasm; however, several authors have suggested alternative differentiation as well as other nosologic categories, including a reactive dermatosis.
  • [MeSH-major] Acanthoma / pathology. Hair Follicle / pathology. Psoriasis / pathology. Skin / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cicatrix / pathology. Dermatitis / pathology. Epidermis / pathology. Female. Hidradenitis Suppurativa / pathology. Humans. Hyperplasia. Keratins / analysis. Keratosis, Seborrheic / pathology. Male. Middle Aged. Molecular Weight. Neoplasms, Basal Cell / pathology. Nerve Tissue Proteins / analysis. Receptors, Nerve Growth Factor / analysis

  • Genetic Alliance. consumer health - Acanthoma.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667172.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NGFR protein, human; 0 / Nerve Tissue Proteins; 0 / Receptors, Nerve Growth Factor; 68238-35-7 / Keratins
  •  go-up   go-down


29. Stacey SN, Gudbjartsson DF, Sulem P, Bergthorsson JT, Kumar R, Thorleifsson G, Sigurdsson A, Jakobsdottir M, Sigurgeirsson B, Benediktsdottir KR, Thorisdottir K, Ragnarsson R, Scherer D, Rudnai P, Gurzau E, Koppova K, Höiom V, Botella-Estrada R, Soriano V, Juberías P, Grasa M, Carapeto FJ, Tabuenca P, Gilaberte Y, Gudmundsson J, Thorlacius S, Helgason A, Thorlacius T, Jonasdottir A, Blondal T, Gudjonsson SA, Jonsson GF, Saemundsdottir J, Kristjansson K, Bjornsdottir G, Sveinsdottir SG, Mouy M, Geller F, Nagore E, Mayordomo JI, Hansson J, Rafnar T, Kong A, Olafsson JH, Thorsteinsdottir U, Stefansson K: Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat Genet; 2008 Nov;40(11):1313-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits.
  • To search for new sequence variants that confer risk of cutaneous basal cell carcinoma (BCC), we conducted a genome-wide SNP association study of 930 Icelanders with BCC and 33,117 controls.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Chromosomes, Human, Pair 1 / genetics. Genetic Predisposition to Disease. Melanoma / genetics. Mutation / genetics. Pigmentation / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adipose Tissue / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Aging. Alleles. Carcinoma, Squamous Cell / genetics. Chromosomal Proteins, Non-Histone / genetics. Chromosomal Proteins, Non-Histone / metabolism. Guanine Nucleotide Exchange Factors / genetics. Guanine Nucleotide Exchange Factors / metabolism. Humans. Middle Aged. Models, Genetic. Polymorphism, Single Nucleotide / genetics. Quantitative Trait, Heritable. RNA / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18849993.001).
  • [ISSN] 1546-1718
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / Guanine Nucleotide Exchange Factors; 0 / RCC2 protein, human; 63231-63-0 / RNA
  •  go-up   go-down


30. Liu Y, Nie H, Bansil R, Steinhart M, Bang J, Lodge TP: Kinetics of disorder-to-fcc phase transition via an intermediate bcc state. Phys Rev E Stat Nonlin Soft Matter Phys; 2006 Jun;73(6 Pt 1):061803
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kinetics of disorder-to-fcc phase transition via an intermediate bcc state.
  • Time-resolved small-angle x-ray scattering measurements reveal that a long-lived intermediate bcc state forms when a poly(styrene-b-isoprene) diblock copolymer solution in an isoprene selective solvent is rapidly cooled from the disordered micellar fluid at high temperature to an equilibrium fcc state.
  • The kinetics of the epitaxial growth of the [111] fcc peak from the [110] bcc peak was obtained by fitting the scattering data to a simple model of the transformation.
  • The growth of the [111] fcc peak agrees with the Avrami model of nucleation and growth kinetics with an exponent n=1.4, as does the initial decay of the [110] bcc peak, with an exponent n=1.3.
  • The data were also found to be in good agreement with the Cahn model of grain boundary nucleation and growth.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16906856.001).
  • [ISSN] 1539-3755
  • [Journal-full-title] Physical review. E, Statistical, nonlinear, and soft matter physics
  • [ISO-abbreviation] Phys Rev E Stat Nonlin Soft Matter Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Bigby SM, Charlton A, Miller MV, Zwi LJ, Oliver GF: Biphasic sarcomatoid basal cell carcinoma (carcinosarcoma): four cases with immunohistochemistry and review of the literature. J Cutan Pathol; 2005 Feb;32(2):141-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biphasic sarcomatoid basal cell carcinoma (carcinosarcoma): four cases with immunohistochemistry and review of the literature.
  • BACKGROUND: Biphasic sarcomatoid carcinoma (BSC), or carcinosarcoma, is an uncommon biphasic neoplasm that has been reported in diverse anatomical sites.
  • The tumor is composed of a malignant epithelial component intimately associated with a malignant mesenchymal component, which may be homologous or heterologous.
  • In only eight of these cases was basal cell carcinoma the epithelial component.
  • METHODS: We report a further four cases of primary cutaneous biphasic basal cell carcinoma, and include the clinical, histological and immunohistochemical features.
  • RESULTS: The four cases showed basal cell carcinoma associated with a pleomorphic sarcomatous stroma.
  • CONCLUSIONS: The sarcomatous component of the tumor is best regarded as a metaplastic transformation of the carcinomatous component.
  • [MeSH-major] Carcinosarcoma / metabolism. Carcinosarcoma / pathology. Skin Neoplasms / metabolism. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Antigens, CD / metabolism. Cell Adhesion Molecules / metabolism. Female. Humans. Immunohistochemistry. Male. Tumor Suppressor Protein p53 / metabolism. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606673.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Tumor Suppressor Protein p53; 0 / Vimentin
  •  go-up   go-down


32. Broers S, Smets E, Bindels P, Evertsz' FB, Calff M, de Haes H: Training general practitioners in behavior change counseling to improve asthma medication adherence. Patient Educ Couns; 2005 Sep;58(3):279-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Training general practitioners in behavior change counseling to improve asthma medication adherence.
  • OBJECTIVE: Adherence to asthma medication regimens is problematic in general practice.
  • We developed and evaluated a communication training for general practitioners (GPs) to help them address medication adherence during routine consultations.
  • This paper describes the development of the training and evaluation results of a pilot study.
  • METHODS: The training was based on behavior change counseling (BCC), a technique derived from motivational interviewing.
  • We developed a five phases BCC consultation model.
  • Participating GPs answered questions at baseline (T0), directly after (T1) and 4-10 months after (T2) the training that assessed their attitudes and confidence regarding adherence communication.
  • They completed evaluation forms at T1 and T2.
  • RESULTS: The 19 participating GPs were positive about the course and the feasibility of BCC in GP consultations.
  • Also, after the training, their attitudes and confidence had improved (p<0.05) and all reported to use BCC skills at least sometimes 4-10 months after the training.
  • CONCLUSION: These positive effects provide us with some hope that the training positively influenced the GP's communication behavior.
  • PRACTICE IMPLICATIONS: If further data on physician behavior and patient outcomes justify implementation of the training, it would then be worthwhile to also involve practice nurses.
  • [MeSH-major] Asthma / drug therapy. Counseling / education. Education, Medical, Continuing. Family Practice / education. Patient Compliance
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Netherlands. Pilot Projects. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024211.001).
  • [ISSN] 0738-3991
  • [Journal-full-title] Patient education and counseling
  • [ISO-abbreviation] Patient Educ Couns
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


33. Kothari M, Simon SR: Chemically modified tetracyclines inhibit VEGF secretion by breast cancer cell lines. Cytokine; 2006 Aug;35(3-4):115-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemically modified tetracyclines inhibit VEGF secretion by breast cancer cell lines.
  • Chemically Modified Tetracyclines (CMTs) are antiproteolytic agents that have been shown to inhibit tumor invasiveness and metastasis.
  • In this study, we report a novel activity of CMT 308, a 9-amino derivative of CMT 300, on reducing levels of VEGF secreted by breast cancer cell lines.
  • CMT 308, at sub-cytotoxic concentrations, reduced basal levels of secreted VEGF in the poorly invasive MCF-7 cell line as well as the more aggressively invasive MDA-MB-435s cell line in a dose-dependent manner.
  • In addition, CMT 308 also reduced transforming growth factor beta (TGFbeta)-induced VEGF secretion in both cell lines.
  • CMT 308 did not reduce the levels of basal VEGF mRNA in either cell line, but did reduce pools of total intracellular VEGF protein.
  • Thus, augmented expression of VEGF protein by breast cancer cell lines in the presence of TGFbeta appears to involve upregulation at a step beyond transcription.
  • Moreover, the data strongly indicate that in these breast cancer cell lines, CMT 308 reduces VEGF secretion by targeting some post-transcriptional event.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / secretion. Tetracyclines / pharmacology. Vascular Endothelial Growth Factor A / secretion
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. Culture Media, Conditioned. Dose-Response Relationship, Drug. Female. Humans. Neoplasm Invasiveness. Neovascularization, Pathologic. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Transforming Growth Factor beta / pharmacology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16978872.001).
  • [ISSN] 1043-4666
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CMT-308; 0 / Culture Media, Conditioned; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Tetracyclines; 0 / Transforming Growth Factor beta; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


34. Indananda C, Matsumoto A, Inahashi Y, Takahashi Y, Duangmal K, Thamchaipenet A: Actinophytocola oryzae gen. nov., sp. nov., isolated from the roots of Thai glutinous rice plants, a new member of the family Pseudonocardiaceae. Int J Syst Evol Microbiol; 2010 May;60(Pt 5):1141-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cell-wall amino acids contained meso-diaminopimelic acid, alanine, glutamic acid and acetylated muramic acid.
  • The whole-cell sugars were arabinose, galactose, mannose, rhamnose and ribose.

  • SILVA. SILVA SSU Database .
  • StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19666784.001).
  • [ISSN] 1466-5026
  • [Journal-full-title] International journal of systematic and evolutionary microbiology
  • [ISO-abbreviation] Int. J. Syst. Evol. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EU420070
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal; 0 / Fatty Acids; 0 / RNA, Ribosomal, 16S
  •  go-up   go-down


35. Martinsson H, Yhr M, Enerbäck C: Expression patterns of S100A7 (psoriasin) and S100A9 (calgranulin-B) in keratinocyte differentiation. Exp Dermatol; 2005 Mar;14(3):161-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They were both absent in undifferentiated basalioma and strongly expressed in carcinoma in situ, as well as in keratoacanthoma and differentiated squamous cell carcinoma.
  • In normal epithelium, they were expressed in the superficial, differentiated region of the epithelium rather than in the basal region.
  • [MeSH-minor] Blotting, Western. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Differentiation / physiology. Cell Line. Computer Systems. Humans. Immunohistochemistry. Keratoacanthoma / metabolism. Keratoacanthoma / pathology. Polymerase Chain Reaction. Reverse Transcriptase Polymerase Chain Reaction. S100 Proteins. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15740587.001).
  • [ISSN] 0906-6705
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Calgranulin B; 0 / S100 Proteins; 0 / S100A7 protein, human
  •  go-up   go-down


36. Hansen CR, Pressler T, Nielsen KG, Jensen PØ, Bjarnsholt T, Høiby N: Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros; 2010 Jan;9(1):51-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Adult. Anti-Bacterial Agents / therapeutic use. Biofilms. Breath Tests. Child. Drug Resistance, Bacterial. Female. Forced Expiratory Volume. Granulocyte Colony-Stimulating Factor / metabolism. Humans. Interferon-gamma / blood. Interferon-gamma / metabolism. Interleukin-10 / metabolism. Interleukin-1beta / metabolism. Interleukin-6 / blood. Interleukin-6 / metabolism. Interleukin-8 / metabolism. Male. Pneumonia, Bacterial / complications. Pneumonia, Bacterial / drug therapy. Pneumonia, Bacterial / immunology. Retrospective Studies. Sputum / metabolism. Sputum / microbiology. Tumor Necrosis Factor-alpha / metabolism. Young Adult

  • Genetic Alliance. consumer health - BabysFirstTest - Cystic Fibrosis.
  • Genetic Alliance. consumer health - Cystic Fibrosis.
  • MedlinePlus Health Information. consumer health - Cystic Fibrosis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19939747.001).
  • [ISSN] 1873-5010
  • [Journal-full-title] Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
  • [ISO-abbreviation] J. Cyst. Fibros.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / IL10 protein, human; 0 / IL6 protein, human; 0 / Interleukin-1beta; 0 / Interleukin-6; 0 / Interleukin-8; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


37. Raaby L, Otkjær K, Salvskov-Iversen ML, Johansen C, Iversen L: A Characterization of the expression of 14-3-3 isoforms in psoriasis, basal cell carcinoma, atopic dermatitis and contact dermatitis. Dermatol Reports; 2010 Aug 31;2(2):e14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Characterization of the expression of 14-3-3 isoforms in psoriasis, basal cell carcinoma, atopic dermatitis and contact dermatitis.
  • 14-3-3 is a highly conserved protein involved in a number of cellular processes including cell signalling, cell cycle regulation and gene transcription.
  • To investigate the expression of the seven 14-3-3 isoforms in involved and uninvolved skin from psoriasis, basal cell carcinoma (BCC), atopic dermatitis and nickel induced allergic contact dermatitis.
  • These results demonstrate a disease specific expression profile of the 14-3-3τ and 14-3-3σ iso-forms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25386251.001).
  • [ISSN] 2036-7392
  • [Journal-full-title] Dermatology reports
  • [ISO-abbreviation] Dermatol Reports
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC4211473
  • [Keywords] NOTNLM ; 14-3-3 proteins / allergic contact dermatitis / atopic dermatitis. / basal cell carcinoma / psoriasis
  •  go-up   go-down


38. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, Valero V: Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol; 2007 Nov 1;25(31):4952-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We estimated the probabilities of death resulting from breast cancer and from other causes, and analyzed associations of patient and tumor characteristics with OS, BCSM, and non-breast cancer-related mortality using the log-rank test, Cox proportional hazards models, and a competing-risk model.
  • Characteristics associated with increased probability of BCSM included age younger than 50 years at diagnosis, high tumor grade, estrogen receptor-negative status, progesterone receptor-negative status, and fewer than six nodes removed at axillary dissection.
  • [MeSH-major] Breast Neoplasms / mortality. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. SEER Program. Survival Analysis. United States

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17971593.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Rigel DS, Torres AM, Ely H: Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report. J Drugs Dermatol; 2008 Jan;7(1 Suppl 1):s15-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report.
  • BACKGROUND: Using more than one therapeutic approach in the treatment of basal cell carcinomas (BCCs) has the potential to enhance cure rates.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / therapy. Curettage. Skin Neoplasms / therapy
  • [MeSH-minor] Administration, Cutaneous. Combined Modality Therapy. Desiccation. Follow-Up Studies. Humans. Neoplasm Recurrence, Local. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277458.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


40. Temme A, Rodriguez JA, Hendruschk S, Günes S, Weigle B, Schäkel K, Schmitz M, Bachmann M, Schackert G, Rieber EP: Nuclear localization of Survivin renders HeLa tumor cells more sensitive to apoptosis by induction of p53 and Bax. Cancer Lett; 2007 Jun 8;250(2):177-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear localization of Survivin renders HeLa tumor cells more sensitive to apoptosis by induction of p53 and Bax.
  • Clinical studies have shown that nuclear expression of the inhibitor of apoptosis protein Survivin in tumor cells predicted a favorable prognosis whereas cytosolic-localized protein caused a decreased overall survival.
  • To address this question, we investigated localization and function of Survivin in normal human lung fibroblasts (NHLFs) and HeLa tumor cells.
  • In addition, transduction of HeLa cells with Survivin fused to a nuclear localization signal augmented basal expression levels of p53 and Bax and enhanced sensitivity for intrinsic apoptosis.
  • A therapeutic intervention which holds Survivin in the nucleus of tumor cells might improve cancer therapy.
  • [MeSH-major] Apoptosis. Cell Nucleus / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Tumor Suppressor Protein p53 / biosynthesis. bcl-2-Associated X Protein / biosynthesis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084966.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / DNA Primers; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


41. Thompson DJ, Healey CS, Baynes C, Kalmyrzaev B, Ahmed S, Dowsett M, Folkerd E, Luben RN, Cox D, Ballinger D, Pharoah PD, Ponder BA, Dunning AM, Easton DF, Studies in Epidemiology and Risks of Cancer Heredity Team: Identification of common variants in the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev; 2008 Dec;17(12):3490-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Haplotype analysis suggested that rs858518, rs727428, or a variant in linkage disequilibrium with them acts to decrease SHBG levels but that this effect is neutralized by rs6259 (D356N).
  • [MeSH-major] Breast Neoplasms / genetics. Genetic Variation. Polymorphism, Single Nucleotide. Postmenopause. Sex Hormone-Binding Globulin / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res. 2008;10(3):R47 [18507837.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Jul;69(1):129-35 [18598274.001]
  • [Cites] J Steroid Biochem Mol Biol. 1999 Sep-Oct;70(4-6):115-21 [10622399.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] Breast Cancer Res. 1999;1(1):14-7 [11250676.001]
  • [Cites] J Biol Chem. 2001 Sep 28;276(39):36383-90 [11473114.001]
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 17;94(8):606-16 [11959894.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1315-20 [12151349.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Dec;88(12):5976-80 [14671199.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):153-9 [14710223.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 16;96(12):936-45 [15199113.001]
  • [Cites] Metabolism. 1997 Sep;46(9):988-91 [9284884.001]
  • [Cites] J Biol Chem. 1998 Dec 18;273(51):34105-14 [9852068.001]
  • [Cites] Br J Cancer. 1999 Jul;80 Suppl 1:95-103 [10466767.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2198-204 [15634719.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1096-101 [15894658.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3653-8 [15755867.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1217-23 [16244653.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):1071-82 [16322344.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):977-85 [16341085.001]
  • [Cites] JAMA. 2006 Mar 15;295(11):1288-99 [16537739.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):675-82 [16614108.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):5029-37 [16926255.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):165-7 [17200668.001]
  • [Cites] BMC Cancer. 2007;7:60 [17411440.001]
  • [Cites] PLoS Genet. 2007 Mar 16;3(3):e42 [17367212.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1087-93 [17529967.001]
  • [Cites] PLoS Genet. 2008 May;4(5):e1000072 [18464913.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):917-24 [14764814.001]
  • (PMID = 19064566.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 10118; United Kingdom / Cancer Research UK / / A10118; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sex Hormone-Binding Globulin
  • [Other-IDs] NLM/ PMC2660245; NLM/ UKMS4231
  • [Investigator] Abraham J; Ahmed S; Antoniou A; Baynes C; Benusiglio P; Blows F; Cebrian A; Conroy D; Curzon B; Dew G; Driver K; Field H; Ghoussaini M; Harrington P; Healey C; Irvine S; Kalmyrzaev B; Jordan C; Lesueur F; Luccarini C; Mayes R; Maranian M; Morrison J; Munday H; Perkins B; Pooley K; Redman K; Scollen S; Shadforth D; Shah M; Simpson A; Stafford A; Thompson D; Tyrer J; Smith P; West J
  •  go-up   go-down


42. Laitman Y, Kaufman B, Lahad EL, Papa MZ, Friedman E: Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer. Isr Med Assoc J; 2007 Nov;9(11):791-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To evaluate whether CHEK2 germline mutations contribute to a breast cancer predisposition in Ashkenazi** Jewish high risk families.
  • [MeSH-major] Breast Neoplasms / genetics. Genetic Predisposition to Disease / ethnology. Germ-Line Mutation / genetics. Jews / genetics. Mutation, Missense / genetics. Protein-Serine-Threonine Kinases / genetics
  • [MeSH-minor] Adult. Aged. Checkpoint Kinase 2. Electrophoresis, Gel, Pulsed-Field. Female. Humans. Israel. Middle Aged. Nucleic Acid Denaturation. Ovarian Neoplasms / epidemiology. Pedigree. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18085035.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] EC 2.7.1.11 / Checkpoint Kinase 2; EC 2.7.11.1 / CHEK2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


43. Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, Marchbanks PA, Simon MS, McDonald JA, Norman SA, Strom BL, Burkman RT, Ursin G, Deapen D, Weiss LK, Folger S, Madeoy JJ, Friedrichsen DM, Suter NM, Humphrey MC, Spirtas R, Ostrander EA: Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res; 2006 Aug 15;66(16):8297-308
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.
  • Although well studied in families at high-risk, the roles of mutations in the BRCA1 and BRCA2 genes are poorly understood in breast cancers in the general population, particularly in Black women and in age groups outside of the very young.
  • We examined the prevalence and predictors of BRCA1 and BRCA2 mutations in 1,628 women with breast cancer and 674 women without breast cancer who participated in a multicenter population-based case-control study of Black and White women, 35 to 64 years of age.
  • Among cases, 2.4% and 2.3% carried deleterious mutations in BRCA1 and BRCA2, respectively.
  • BRCA1 mutations were significantly more common in White (2.9%) versus Black (1.4%) cases and in Jewish (10.2%) versus non-Jewish (2.0%) cases; BRCA2 mutations were slightly more frequent in Black (2.6%) versus White (2.1%) cases.
  • Numerous familial and demographic factors were significantly associated with BRCA1 and, to a lesser extent, BRCA2 carrier status, when examined individually.
  • In models considering all predictors together, early onset ages in cases and in relatives, family history of ovarian cancer, and Jewish ancestry remained strongly and significantly predictive of BRCA1 carrier status, whereas BRCA2 predictors were fewer and more modest in magnitude.
  • Both the combinations of predictors and effect sizes varied across racial/ethnic and age groups.
  • These results provide first-time prevalence estimates for BRCA1/BRCA2 in breast cancer cases among understudied racial and age groups and show key predictors of mutation carrier status for both White and Black women and women of a wide age spectrum with breast cancer in the general population.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Res. 2007 May 15;67(10):5057; author reply 5057-8 [17510441.001]
  • (PMID = 16912212.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / N01 HD 3-3175; United States / NICHD NIH HHS / HD / N01 HD 2-3166; United States / NICHD NIH HHS / HD / N01 HD 3-3176; United States / NCI NIH HHS / CN / N01-CN-0532; United States / NCI NIH HHS / PC / N01-PC-67006; United States / Intramural NIH HHS / / ; United States / NICHD NIH HHS / HD / Y01 HD 7022; United States / NICHD NIH HHS / HD / N01 HD 3-3174; United States / NCI NIH HHS / CN / N01-CN-67010; United States / NICHD NIH HHS / HD / N01 HD 3-3168; United States / NCI NIH HHS / CN / N01-CN-65064; United States / NCI NIH HHS / CA / T32 CA080416
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / BRCA2 Protein
  •  go-up   go-down


44. Hu MB, Xie W, Xiong B, Han DF, Li Y, Feng MH, Zhou YF: [Study on the relationship between polymorphisms of genes (CYP17, CYP19 and SULT1A1) and susceptibility to breast cancer in Chinese women]. Zhonghua Liu Xing Bing Xue Za Zhi; 2006 Apr;27(4):351-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Aromatase / genetics. Arylsulfotransferase / genetics. Breast Neoplasms / genetics. Genetic Predisposition to Disease. Steroid 17-alpha-Hydroxylase / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875543.001).
  • [ISSN] 0254-6450
  • [Journal-full-title] Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
  • [ISO-abbreviation] Zhonghua Liu Xing Bing Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.14.14.1 / Aromatase; EC 1.14.99.9 / Steroid 17-alpha-Hydroxylase; EC 2.8.2.1 / Arylsulfotransferase; EC 2.8.2.1 / SULT1A1 protein, human
  •  go-up   go-down


45. Karppinen SM, Barkardottir RB, Backenhorn K, Sydenham T, Syrjäkoski K, Schleutker J, Ikonen T, Pylkäs K, Rapakko K, Erkko H, Johannesdottir G, Gerdes AM, Thomassen M, Agnarsson BA, Grip M, Kallioniemi A, Kere J, Aaltonen LA, Arason A, Møller P, Kruse TA, Borg A, Winqvist R: Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies. J Med Genet; 2006 Nov;43(11):856-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: BARD1 was originally identified as a BRCA1-interacting protein but has also been described in tumour-suppressive functions independent of BRCA1.
  • [MeSH-major] Alleles. Breast Neoplasms / genetics. Mutation, Missense. Tumor Suppressor Proteins / genetics. Ubiquitin-Protein Ligases / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / genetics. Case-Control Studies. Cohort Studies. Colorectal Neoplasms / genetics. DNA Mutational Analysis. Female. Genes, BRCA1. Genes, BRCA2. Genetic Predisposition to Disease. Genetic Testing. Humans. Male. Middle Aged. Ovarian Neoplasms / genetics. Prostatic Neoplasms / genetics


46. Gunia S, Liebe D, Koch S: Loss of basal cell keratin 14 reflects increased risk of recurrence in surgically resected sinonasal inverted papilloma. J Clin Pathol; 2008 Jun;61(6):707-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of basal cell keratin 14 reflects increased risk of recurrence in surgically resected sinonasal inverted papilloma.
  • RESULTS: Increased proliferative activity (Ki67) and loss of basal cell keratin 14 (CK14) expression were related to the development of recurrence in microsurgically resected SIP.
  • CONCLUSION: These findings might advance understanding of the pathogenesis behind the development of recurrence in microsurgically resected SIP by focusing on so far neglected alterations of cell-matrix connections at the epithelial-stromal interface in SIP, and might hint at CK14 representing a possible novel biomarker for individual risk assessment in microsurgically resected SIP.
  • [MeSH-major] Biomarkers, Tumor / analysis. Keratin-14 / analysis. Ki-67 Antigen / analysis. Neoplasm Recurrence, Local / metabolism. Papilloma, Inverted / metabolism. Paranasal Sinus Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Cell Proliferation. Databases, Factual. Female. Humans. Male. Microsurgery. Middle Aged. Proportional Hazards Models. Retrospective Studies. Risk. Staining and Labeling. Statistics, Nonparametric

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18505889.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-14; 0 / Ki-67 Antigen
  •  go-up   go-down


47. del Rey J, Placer J, Vallmanya F, Pujol N, Prat E, Miró R, Gelabert A: Are patients with non-muscle-invasive bladder cancer a suitable population for a lung cancer screening trial? BJU Int; 2010 Jul;106(1):49-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To estimate the relative risk of developing a second primary neoplasm, in particular lung cancer, after having non-muscle-invasive bladder cancer (NMIBC).
  • The interval between neoplasms, smoking habits, histological subtypes and survival were also analysed.
  • RESULTS: We found 231 patients with NMIBC, 39 of which had a second primary neoplasm: 10 lung cancer, one pancreas, one gastric, one pharynx, one liver, one parathyroid, one oesophageal, five basal cell carcinoma, three larynx, two colon, three rectal and 10 prostate.
  • In patients with lung cancer, NMIBC was the first primary tumour.
  • This proposal is reinforced by the finding that death in our group of patients with both tumours was always derived from lung cancer and not from bladder cancer.
  • [MeSH-major] Carcinoma, Transitional Cell. Early Detection of Cancer. Lung Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis. Urinary Bladder Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Risk Factors


48. Rodust PM, Stockfleth E, Ulrich C, Leverkus M, Eberle J: UV-induced squamous cell carcinoma--a role for antiapoptotic signalling pathways. Br J Dermatol; 2009 Nov;161 Suppl 3:107-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] UV-induced squamous cell carcinoma--a role for antiapoptotic signalling pathways.
  • The incidence of nonmelanoma skin cancer including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) has dramatically increased in the last decades, and chronic sun exposure was identified as a main etiologic agent.
  • As mutations caused by UV may lead to skin cancer due to oncogene activation and tumor suppressor gene inactivation, efficient safeguard mechanisms have been developed during evolution.
  • The keratinocyte apoptotic machinery in response to UV consists of both intrinsic/mitochondrial and extrinsic/death receptor-mediated cell-death pathways, which are particularly regulated by mitogen-activated protein kinases (MAPKs, JNK and p38) and the tumor-suppressor protein p53.
  • [MeSH-major] Apoptosis. Carcinoma, Squamous Cell / etiology. DNA Damage. Signal Transduction / radiation effects. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / pathology. Humans. Mitochondria / genetics. Mitochondria / pathology. Mitochondria / radiation effects. Neoplasms, Radiation-Induced / etiology. Neoplasms, Radiation-Induced / genetics. Neoplasms, Radiation-Induced / pathology. Skin Neoplasms / etiology. Skin Neoplasms / genetics. Skin Neoplasms / pathology. TNF-Related Apoptosis-Inducing Ligand / metabolism


49. Kurdi P, Smitinont T, Valyasevi R: Isolation and characterization of acid-sensitive mutants of Pediococcus acidilactici. Food Microbiol; 2009 Feb;26(1):82-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Cell Membrane / metabolism. Meat Products / microbiology. Mutation. Pediococcus. Proton-Translocating ATPases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19028310.001).
  • [ISSN] 1095-9998
  • [Journal-full-title] Food microbiology
  • [ISO-abbreviation] Food Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fatty Acids; EC 3.6.3.14 / Proton-Translocating ATPases
  •  go-up   go-down


50. Wang X, Wu X, Liang Z, Huang Y, Fenech M, Xue J: A comparison of folic acid deficiency-induced genomic instability in lymphocytes of breast cancer patients and normal non-cancer controls from a Chinese population in Yunnan. Mutagenesis; 2006 Jan;21(1):41-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results showed that 30 nM FA was associated with increased frequencies of micronucleated binucleated cell (MNed BNC), nucleoplasmic bridges (NPB), nuclear buds (BUD), apoptosis (APO) and necrosis (NEC) relative to 120 and 240 nM FA (P<0.001) in lymphocytes of case and control groups in vitro, however there were no significant differences between the 120 and 240 nM FA within each sampling group.
  • We concluded that (i) increased concentrations of FA abolished the genome-damaging effect of FA deficiency in lymphocytes of both breast cancer patients and controls to a similar extent and (ii) FA concentration is much more important than breast cancer status in determining genomic instability and cell death.
  • [MeSH-major] Breast Neoplasms. Folic Acid Deficiency / metabolism. Genomic Instability. Lymphocytes / drug effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16339195.001).
  • [ISSN] 0267-8357
  • [Journal-full-title] Mutagenesis
  • [ISO-abbreviation] Mutagenesis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid
  •  go-up   go-down


51. Guldner L, Multigner L, Héraud F, Monfort C, Thomé JP, Giusti A, Kadhel P, Cordier S: Pesticide exposure of pregnant women in Guadeloupe: ability of a food frequency questionnaire to estimate blood concentration of chlordecone. Environ Res; 2010 Feb;110(2):146-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pesticide exposure of pregnant women in Guadeloupe: ability of a food frequency questionnaire to estimate blood concentration of chlordecone.
  • CONTEXT: Chlordecone, an environmentally persistent organochlorine insecticide used intensively in banana culture in the French West Indies until 1993, has permanently polluted soils and contaminated foodstuffs.
  • Consumption of contaminated food is the main source of exposure nowadays.
  • We sought to identify main contributors to blood chlordecone concentration (BCC) and to validate an exposure indicator based on food intakes.
  • MATERIAL AND METHODS: We used a food frequency questionnaire (FFQ) completed by a sample of 194 pregnant women to estimate their dietary exposure to chlordecone and compared it to blood levels.
  • In a first approach, chlordecone daily intake was estimated as the product of daily eaten quantity of 214 foodstuffs, multiplied by their chlordecone content, and summed over all items.
  • We then predicted individual blood chlordecone concentration with empirical weight regression models based on frequency of food consumption, and without contamination data.
  • RESULTS: Among the 191 subjects who had BCC determination, 146 (76%) had detectable values and mean BCC was 0.86 ng/mL (range < LOD-13.2).
  • Mean per capita dietary intake of chlordecone was estimated at 3.3 microg/day (range: 0.1-22.2).
  • Blood chlordecone levels were significantly correlated with food exposure predicted from the empirical weight models (r=0.47, p<0.0001) and, to a lesser extent, with chlordecone intake estimated from food consumption and food contamination data (r=0.20, p=0.007).
  • Main contributors to chlordecone exposure included seafood, root vegetables, and Cucurbitaceous.
  • CONCLUSION: These results show that the Timoun FFQ provides valid estimates of chlordecone exposure.
  • Estimates from empirical weight models correlated better with blood levels of chlordecone than did estimates from the dietary intake assessment.
  • [MeSH-major] Chlordecone / blood. Food Contamination. Pesticides / blood. Pregnancy / blood. Soil Pollutants / blood
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Diet. Environmental Exposure. Female. Guadeloupe. Humans. Middle Aged. Prospective Studies. Regression Analysis. Socioeconomic Factors. Surveys and Questionnaires. Young Adult

  • MedlinePlus Health Information. consumer health - Foodborne Illness.
  • MedlinePlus Health Information. consumer health - Pesticides.
  • MedlinePlus Health Information. consumer health - Pregnancy.
  • HAL archives ouvertes. Full text from .
  • Hazardous Substances Data Bank. KEPONE .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Inc. All rights reserved.
  • (PMID = 20003965.001).
  • [ISSN] 1096-0953
  • [Journal-full-title] Environmental research
  • [ISO-abbreviation] Environ. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pesticides; 0 / Soil Pollutants; RG5XJ88UDF / Chlordecone
  •  go-up   go-down


52. Nonaka K, Arai S, Ishikawa K, Nakao M, Nakai Y, Togawa O, Nagata K, Shimizu M, Sasaki Y, Kita H: Short term results of endoscopic submucosal dissection in superficial esophageal squamous cell neoplasms. World J Gastrointest Endosc; 2010 Feb 16;2(2):69-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short term results of endoscopic submucosal dissection in superficial esophageal squamous cell neoplasms.
  • AIM: To evaluate the efficacy of endoscopic submucosal dissection for superficial esophageal squamous cell neoplasms.
  • METHODS: Between July 2007 and March 2009, 27 consecutive superficial esophageal squamous cell neoplasms in 25 enrolled patients were treated by endoscopic submucosal dissection.
  • The en block resection rate was 100% (27/27), and en block resection with tumor-free lateral/basal margins was 88.9% (24/27).
  • CONCLUSION: Endoscopic submucosal dissection is applicable to superficial esophageal squamous cell neoplasms with promising results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160693.001).
  • [ISSN] 1948-5190
  • [Journal-full-title] World journal of gastrointestinal endoscopy
  • [ISO-abbreviation] World J Gastrointest Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999061
  • [Keywords] NOTNLM ; Endoscopic submucosal dissection / Endoscopy / Esophageal cancer / Neoplasm / Squamous cell
  •  go-up   go-down


53. Soulairol R, Fu CC, Barreteau C: Structure and magnetism of bulk Fe and Cr: from plane waves to LCAO methods. J Phys Condens Matter; 2010 Jul 28;22(29):295502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structure and magnetism of bulk Fe and Cr: from plane waves to LCAO methods.
  • Magnetic, structural and energetic properties of bulk Fe and Cr were studied using first-principles calculations within density functional theory (DFT).
  • We aimed to identify the dependence of these properties on key approximations of DFT, namely the exchange-correlation functional, the pseudopotential and the basis set.
  • We found a smaller effect of pseudopotentials (PPs) on Fe than on Cr.
  • For instance, the local magnetism of Cr was shown to be particularly sensitive to the potentials representing the core electrons, i.e. projector augmented wave and Vanderbilt ultrasoft PPs predict similar results, whereas standard norm-conserving PPs tend to overestimate the local magnetic moments of Cr in bcc Cr and in dilute bcc FeCr alloys.
  • This drawback is suggested to be closely correlated to the overestimation of Cr solution energy in the latter system.
  • On the other hand, we point out that DFT methods with very reduced localized basis sets (LCAO: linear combination of atomic orbitals) give satisfactory results compared with more robust plane-wave approaches.
  • A minimal-basis representation of '3d' electrons comes to be sufficient to describe non-trivial magnetic phases including spin spirals in both fcc Fe and bcc Cr, as well as the experimental magnetic ground state of bcc Cr showing a spin density wave (SDW) state.
  • In addition, a magnetic 'spd' tight binding model within the Stoner formalism was proposed and validated for Fe and Cr.
  • The respective Stoner parameters were obtained by fitting to DFT data.
  • This efficient semiempirical approach was shown to be accurate enough for studying various collinear and non-collinear phases of bulk Fe and Cr.
  • It also enabled a detailed investigation of different polarization states of SDW in bcc Cr, where the longitudinal state was suggested to be the ground state, consistent with existing experimental data.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21399309.001).
  • [ISSN] 1361-648X
  • [Journal-full-title] Journal of physics. Condensed matter : an Institute of Physics journal
  • [ISO-abbreviation] J Phys Condens Matter
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


54. de Longueville F, Lacroix M, Barbuto AM, Bertholet V, Gallo D, Larsimont D, Marcq L, Zammatteo N, Boffe S, Leclercq G, Remacle J: Molecular characterization of breast cancer cell lines by a low-density microarray. Int J Oncol; 2005 Oct;27(4):881-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of breast cancer cell lines by a low-density microarray.
  • We designed a low-density microarray carrying 132 DNA capture sequences highly specific for genes known to be differentially expressed among breast tumors and BCC lines or associated with specific tumor properties (cell-cycle alteration, proteolysis, adhesion, hormone sensitivity, etc).
  • Some data obtained were verified or extended by real-time polymerase chain reaction (real-time PCR), Northern blotting, Western blotting, immunohistochemistry and cell growth studies.
  • A few genes that are highly and specifically expressed in one cell line were identified, such as MGB1 (mammaglobin 1) in Evsa-T cells, and PIP (prolactin-inducible protein) in MDA-MB-453 BCC, suggesting an apocrine origin for these latter cells.
  • In conclusion, our results support the utility of a low-density microarray approach in cases where the cost and exhaustiveness of high-density microarrays may constitute a drawback; for instance, in obtaining a rapid phenotype evaluation in cell populations freshly isolated from breast tumors.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Biotinylation. Blotting, Northern. Blotting, Western. Cell Adhesion. Cell Line, Tumor. Cell Proliferation. Cluster Analysis. DNA, Complementary / metabolism. Estrogen Receptor alpha / metabolism. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Mammaglobin A. Neoplasm Proteins / metabolism. Nucleic Acid Hybridization. Phenotype. Polymerase Chain Reaction. RNA / metabolism. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Uteroglobin / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142302.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Estrogen Receptor alpha; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / SCGB2A2 protein, human; 63231-63-0 / RNA; 9060-09-7 / Uteroglobin
  •  go-up   go-down


55. Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L: Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. Cancer Res; 2010 Nov 1;70(21):8852-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four hundred twenty-eight protein kinases in gene expression data were examined from 684 cases of breast cancer and 51 breast cancer cell lines to identify kinase expression patterns.
  • Downregulation of these kinases caused significant subtype-specific inhibition of cell growth in vitro.
  • [MeSH-major] Breast Neoplasms / classification. Breast Neoplasms / metabolism. Protein Kinases / chemistry. Protein Kinases / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Female. Gene Expression Profiling. Humans. Prognosis. RNA, Small Interfering / pharmacology. Survival Rate. Tumor Cells, Cultured


56. Moore AB, Shannon J, Chen C, Lampe JW, Ray RM, Lewis SK, Lin M, Stalsberg H, Thomas DB: Dietary and stored iron as predictors of breast cancer risk: A nested case-control study in Shanghai. Int J Cancer; 2009 Sep 1;125(5):1110-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increases in risk of breast cancer in successive generations of migrants to the United States from China and rapid temporal changes in incidence rates in China following social and economic changes clearly implicate environmental factors in the etiology of this disease.
  • Iron, an essential element necessary for cell function, has also been demonstrated to have potential carcinogenic and co-carcinogenic activities.
  • In conclusion, this study finds significant associations between iron (stored and dietary) and fibrocystic disease and breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 UICC.
  • [Cites] Free Radic Biol Med. 1996;20(4):553-66 [8904296.001]
  • [Cites] Cancer Res. 1990 Jun 1;50(11):3176-81 [2334913.001]
  • [Cites] Exp Cell Res. 1985 Dec;161(2):277-84 [2998833.001]
  • [Cites] Int J Vitam Nutr Res. 1986;56(3):281-6 [3781753.001]
  • [Cites] Cancer Res. 1987 Nov 1;47(21):5771-6 [3664480.001]
  • [Cites] Cancer Lett. 1988 Aug 30;41(3):251-6 [3409203.001]
  • [Cites] Anticancer Res. 1989 Nov-Dec;9(6):1477-82 [2560618.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 5;89(5):355-65 [9060957.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):333-9 [9139863.001]
  • [Cites] Br J Radiol. 1997 Apr;70(832):375-82 [9166074.001]
  • [Cites] Carcinogenesis. 1997 Sep;18(9):1757-62 [9328172.001]
  • [Cites] Arch Biochem Biophys. 1997 Oct 15;346(2):180-6 [9343364.001]
  • [Cites] Cancer Causes Control. 1998 Jan;9(1):19-27 [9486460.001]
  • [Cites] J Epidemiol Community Health. 1998 Feb;52(2):105-10 [9578857.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):81-90 [15668480.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):243-50 [15668501.001]
  • [Cites] Int J Cancer. 2005 Jul 20;115(6):981-93 [15723298.001]
  • [Cites] Am J Epidemiol. 2005 Jun 15;161(12):1115-22 [15937020.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2889-97 [16365006.001]
  • [Cites] Phys Med Biol. 2007 Jul 7;52(13):3895-911 [17664584.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1682-5 [17684146.001]
  • [Cites] Lancet Oncol. 2008 Aug;9(8):803-7 [18672216.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):771-83 [12866039.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1159-67 [14652275.001]
  • [Cites] J Nutr. 2003 Nov;133(11 Suppl 2):3898S-3906S [14672288.001]
  • [Cites] Nutr Cancer. 2003;46(2):131-7 [14690788.001]
  • [Cites] Phys Med Biol. 2004 Jan 7;49(1):99-110 [14971775.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):205-12 [14973098.001]
  • [Cites] Ann Epidemiol. 2004 Mar;14(3):195-201 [15036223.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1106-13 [15247120.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1450-8 [15150082.001]
  • [Cites] N Engl J Med. 1974 May 30;290(22):1213-6 [4825851.001]
  • [Cites] N Engl J Med. 1975 May 1;292(18):951-6 [1090831.001]
  • [Cites] Scand J Haematol Suppl. 1977;32:87-98 [272039.001]
  • [Cites] Clin Chem. 1981 Jan;27(1):78-82 [7449126.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] Public Health Nutr. 1998 Sep;1(3):139-45 [10933411.001]
  • [Cites] Int J Cancer. 2001 Jan 15;91(2):260-3 [11146455.001]
  • [Cites] Curr Med Chem. 2001 Jun;8(7):839-49 [11375754.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 2;94(19):1445-57 [12359854.001]
  • [Cites] Anticancer Res. 2002 Sep-Oct;22(5):2685-92 [12529982.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3797-9 [12552996.001]
  • [Cites] Biomed Environ Sci. 2002 Dec;15(4):271-6 [12642982.001]
  • [Cites] Environ Health Perspect. 1990 Jul;87:291-300 [2269234.001]
  • [Cites] Carcinogenesis. 1991 Jan;12(1):111-4 [1988169.001]
  • [Cites] Cancer. 1991 Mar 15;67(6):1707-12 [2001562.001]
  • [Cites] Am J Clin Nutr. 1991 Oct;54(4):729-35 [1897480.001]
  • [Cites] Med Oncol Tumor Pharmacother. 1991;8(4):229-33 [1820488.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3896-907 [8389654.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 17;85(22):1819-27 [8230262.001]
  • [Cites] Int J Cancer. 1994 Feb 1;56(3):364-9 [8314323.001]
  • [Cites] Int J Cancer. 1994 Feb 1;56(3):379-82 [8314326.001]
  • [Cites] Jpn J Cancer Res. 1994 Jun;85(6):572-7 [8063609.001]
  • [Cites] Br J Cancer. 1995 Jun;71(6):1353-8 [7779738.001]
  • [Cites] J Natl Cancer Inst. 1995 Aug 2;87(15):1154-61 [7674320.001]
  • [Cites] Int J Cancer. 1996 Jan 17;65(2):140-4 [8567108.001]
  • [Cites] Eur J Cancer Prev. 1996 Feb;5(1):19-36 [8664805.001]
  • [Cites] Toxicol Appl Pharmacol. 1996 Aug;139(2):356-64 [8806853.001]
  • [Cites] Am J Epidemiol. 1996 Oct 1;144(7):653-60 [8823061.001]
  • [Cites] Cancer Causes Control. 1996 Jan;7(1):56-68 [8850435.001]
  • [Cites] Am J Clin Nutr. 1982 May;35(5 Suppl):1180-5 [7044096.001]
  • [Cites] J Nutr. 1985 Mar;115(3):369-74 [3973748.001]
  • [Cites] Exp Cell Res. 1996 Nov 25;229(1):60-8 [8940249.001]
  • (PMID = 19444907.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA075332-05; United States / NCI NIH HHS / CA / R01 CA075332; United States / NCI NIH HHS / CA / R01 CA075332-05; United States / NCI NIH HHS / CA / R01-CA75332
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iron Compounds; 0 / Iron, Dietary; 9007-73-2 / Ferritins
  • [Other-IDs] NLM/ NIHMS163587; NLM/ PMC2798105
  •  go-up   go-down


57. Zuccolo L, Pastore G, Pearce N, Mosso ML, Merletti F, Magnani C: Mortality from cancer and other causes in parents of children with cancer: a population-based study in Piedmont, Italy. Eur J Cancer Prev; 2007 Oct;16(5):390-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Neoplasms / genetics. Neoplasms / mortality. Parents

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17923808.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


58. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat; 2008 May;109(1):123-39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of basal-like breast cancer.
  • Risk factors for the newly identified "intrinsic" breast cancer subtypes (luminal A, luminal B, basal-like and human epidermal growth factor receptor 2-positive/estrogen receptor-negative) were determined in the Carolina Breast Cancer Study, a population-based, case-control study of African-American and white women.
  • Basal-like cases exhibited several associations that were opposite to those observed for luminal A, including increased risk for parity and younger age at first term full-term pregnancy.
  • Longer duration breastfeeding, increasing number of children breastfed, and increasing number of months breastfeeding per child were each associated with reduced risk of basal-like breast cancer, but not luminal A.
  • Women with multiple live births who did not breastfeed and women who used medications to suppress lactation were at increased risk of basal-like, but not luminal A, breast cancer.
  • Elevated waist-hip ratio was associated with increased risk of luminal A in postmenopausal women, and increased risk of basal-like breast cancer in pre- and postmenopausal women.
  • The prevalence of basal-like breast cancer was highest among premenopausal African-American women, who also showed the highest prevalence of basal-like risk factors.
  • Among younger African-American women, we estimate that up to 68% of basal-like breast cancer could be prevented by promoting breastfeeding and reducing abdominal adiposity.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2006 Sep;37(9):1217-26 [16938528.001]
  • [Cites] Environ Health. 2006;5:21 [16859537.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8327-30 [16951137.001]
  • [Cites] CA Cancer J Clin. 2006 Sep-Oct;56(5):254-81; quiz 313-4 [17005596.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1871-7 [17035393.001]
  • [Cites] Arch Intern Med. 2006 Nov 13;166(20):2244-52 [17101943.001]
  • [Cites] Arch Intern Med. 2006 Nov 13;166(20):2253-9 [17101944.001]
  • [Cites] Breast Cancer Res. 2006;8(4):R34 [16846532.001]
  • [Cites] Breast Cancer Res. 2006;8(4):R43 [16859501.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):197-204 [17234468.001]
  • [Cites] Science. 2007 Feb 2;315(5812):592-4 [17272699.001]
  • [Cites] Obesity (Silver Spring). 2007 Feb;15(2):430-45 [17299117.001]
  • [Cites] Epidemiology. 2007 Mar;18(2):234-9 [17237733.001]
  • [Cites] Epidemiology. 2007 Mar;18(2):280-1 [17301710.001]
  • [Cites] Arch Intern Med. 2007 Feb 26;167(4):408-15 [17325304.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):439-43 [17372238.001]
  • [Cites] Cancer. 2007 May 1;109(9):1721-8 [17387718.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;102(1):85-101 [17080310.001]
  • [Cites] Annu Rev Nutr. 2007;27:103-21 [17341160.001]
  • [Cites] Lancet. 2002 Jul 20;360(9328):187-95 [12133652.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):823 [12192390.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):211-21 [12491484.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):222-9 [12491485.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):273-9 [12491491.001]
  • [Cites] J Nutr. 2003 Jan;133(1):305S-309S [12514315.001]
  • [Cites] Obes Res. 1998 Sep;6 Suppl 2:51S-209S [9813653.001]
  • [Cites] Epidemiology. 1999 Jan;10(1):37-48 [9888278.001]
  • [Cites] Ann Epidemiol. 1999 Apr;9(3):188-95 [10192651.001]
  • [Cites] Int J Epidemiol. 1999 Jun;28(3):396-402 [10405840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9212-7 [10430922.001]
  • [Cites] Am J Epidemiol. 2005 Jan 1;161(1):40-51 [15615914.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):439-48 [15770008.001]
  • [Cites] Breast Cancer Res Treat. 1999 Nov;58(1):31-9 [10634516.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):65-71 [10667465.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 16;92(4):302-12 [10675379.001]
  • [Cites] Am J Epidemiol. 2000 Apr 1;151(7):703-14 [10752798.001]
  • [Cites] Cancer Causes Control. 2000 Apr;11(4):345-57 [10843445.001]
  • [Cites] Am J Public Health. 2000 Jun;90(6):966-71 [10846517.001]
  • [Cites] J Appl Physiol (1985). 2000 Aug;89(2):636-43 [10926648.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):478-83 [12644541.001]
  • [Cites] Cancer Causes Control. 2003 Mar;14(2):151-60 [12749720.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jun;79(3):355-64 [12846420.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Obes Rev. 2003 Aug;4(3):157-73 [12916817.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 4;96(3):218-28 [14759989.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1595-604 [15073845.001]
  • [Cites] Nat Rev Immunol. 2004 Jul;4(7):565-72 [15229475.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):353-62 [15241834.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):762-71 [15252848.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 21;96(14):1094-8 [15265971.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1558-68 [15466970.001]
  • [Cites] Am J Epidemiol. 1985 Nov;122(5):904-14 [4050778.001]
  • [Cites] Am J Pathol. 1989 Mar;134(3):571-9 [2466404.001]
  • [Cites] Am J Epidemiol. 1991 Aug 15;134(4):421-32 [1877602.001]
  • [Cites] Am J Epidemiol. 1992 Dec 15;136(12):1445-56 [1288274.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Mar;3(2):173-5 [8049640.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Jan-Feb;4(1):11-9 [7894319.001]
  • [Cites] Breast Cancer Res Treat. 1995 Jul;35(1):51-60 [7612904.001]
  • [Cites] Metabolism. 1996 Sep;45(9):1119-24 [8781299.001]
  • [Cites] JAMA. 1998 Mar 25;279(12):915-21 [9544765.001]
  • [Cites] Cell Mol Life Sci. 2007 Dec;64(24):3219-32 [17957336.001]
  • [Cites] Am J Epidemiol. 1998 May 1;147(9):826-33 [9583712.001]
  • [Cites] Am J Public Health. 1998 Jan;88(1):15-9 [9584027.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):371-8 [9610785.001]
  • [Cites] Eur J Cancer Prev. 2001 Feb;10(1):15-32 [11263588.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] J Natl Med Assoc. 2001 Sep;93(9):329-34 [11560288.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):445-52 [11992416.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):601-7 [12101106.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):429-34 [15736216.001]
  • [Cites] Breast Cancer Res Treat. 2005 Mar;90(2):127-37 [15803359.001]
  • [Cites] Int J Cancer. 2005 Sep 1;116(3):340-50 [15818618.001]
  • [Cites] Am J Epidemiol. 2005 Aug 1;162(3):229-37 [15987723.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):1059-69 [16322343.001]
  • [Cites] Oncology. 2005;69(6):478-85 [16410686.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1447-53 [16533767.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1342-9 [16549828.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2170-8 [16682736.001]
  • [Cites] Cell Cycle. 2006 May;5(9):963-7 [16687925.001]
  • [Cites] BMC Genomics. 2006;7:96 [16643655.001]
  • [Cites] CA Cancer J Clin. 2006 May-Jun;56(3):168-83 [16737949.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] BMC Genomics. 2006;7:127 [16729877.001]
  • [Cites] Eur J Cancer Prev. 2006 Aug;15(4):306-42 [16835503.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):560-9 [16899776.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8297-308 [16912212.001]
  • [ErratumIn] Breast Cancer Res Treat. 2008 May;109(1):141. Dressler, Lynn G [added]
  • (PMID = 17578664.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA058223-140021; United States / NCI NIH HHS / CA / CA016086-259034; United States / NCI NIH HHS / CA / CA058223-150021; United States / NCI NIH HHS / CA / R01 CA101227; United States / NCI NIH HHS / CA / CA058223-09A10013; United States / NCI NIH HHS / CA / P30 CA016086; United States / NCI NIH HHS / CA / P30 CA016086-259034; United States / NCI NIH HHS / CA / P50 CA058223-150021; United States / NCI NIH HHS / CA / P50 CA058223; United States / NCI NIH HHS / CA / P50-CA58223; United States / NCI NIH HHS / CA / CA058223-100013; United States / NCI NIH HHS / CA / P50 CA058223-140021; United States / NCI NIH HHS / CA / P30-CA16086; United States / NCI NIH HHS / CA / P50 CA058223-100013; United States / NCI NIH HHS / CA / R01-CA101227; United States / NCI NIH HHS / CA / P50 CA058223-09A10013
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS50834; NLM/ PMC2443103
  •  go-up   go-down


59. Murphy MM, Zayed MA, Evans A, Parker CE, Ataga KI, Telen MJ, Parise LV: Role of Rap1 in promoting sickle red blood cell adhesion to laminin via BCAM/LU. Blood; 2005 Apr 15;105(8):3322-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of Rap1 in promoting sickle red blood cell adhesion to laminin via BCAM/LU.
  • Vaso-occlusion is a hallmark of sickle cell disease.
  • Here, we investigated whether Rap1, a small guanosine triphosphatase (GTPase) known to promote integrin-mediated adhesion in other cells, was involved in this signaling pathway.
  • However, this adhesion was completely inhibited by either a soluble version of basal cell adhesion molecule/Lutheran (BCAM/LU) or a BCAM/LU adhesion-blocking anti-body.
  • Surprisingly, 8CPT-2-Me-activated Rap1 did not promote SS RBC adhesion to a known alpha4beta1 ligand, vascular cell adhesion molecule 1 (VCAM-1).
  • [MeSH-major] Anemia, Sickle Cell / blood. Cell Adhesion / physiology. Cell Adhesion Molecules / metabolism. Laminin / metabolism. Neoplasm Proteins / metabolism. rap1 GTP-Binding Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Sickle Cell Anemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613546.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / 1-R01-HL67440-01; United States / NHLBI NIH HHS / HL / HL58939; United States / NHLBI NIH HHS / HL / HL63409; United States / NCRR NIH HHS / RR / RR0046
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCAM protein, human; 0 / Cell Adhesion Molecules; 0 / Guanine Nucleotide Exchange Factors; 0 / Laminin; 0 / Lutheran Blood-Group System; 0 / Neoplasm Proteins; 0 / RAPGEF3 protein, human; E0399OZS9N / Cyclic AMP; EC 3.6.5.2 / rap1 GTP-Binding Proteins
  •  go-up   go-down


60. Ortix C, Lorenzana J, Di Castro C: Coulomb-frustrated phase separation phase diagram in systems with short-range negative compressibility. Phys Rev Lett; 2008 Jun 20;100(24):246402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coulomb-frustrated phase separation phase diagram in systems with short-range negative compressibility.
  • Using numerical techniques and asymptotic expansions we obtain the phase diagram of a paradigmatic model of Coulomb-frustrated phase separation in systems with negative short-range compressibility.
  • The transition from the homogeneous phase to the inhomogeneous phase is generically first order in isotropic three-dimensional systems except for a critical point.
  • Close to the critical point, inhomogeneities are predicted to form a bcc lattice with subsequent transitions to a triangular lattice of rods and a layered structure.
  • Inclusion of a strong anisotropy allows for second- and first-order transition lines joined by a tricritical point.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18643604.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Mehta S, Price GD, Alfè D: Ab initio thermodynamics and phase diagram of solid magnesium: a comparison of the LDA and GGA. J Chem Phys; 2006 Nov 21;125(19):194507
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ab initio thermodynamics and phase diagram of solid magnesium: a comparison of the LDA and GGA.
  • The finite temperature density functional theory and quasiharmonic lattice dynamics have been used to compute numerous thermodynamic properties of hexagonal close packed magnesium using both the local density approximation (LDA) and the generalized gradient approximation (GGA) for the exchange-correlation potential.
  • Generally, it is found that there exist only minor differences between the LDA and GGA computed properties, with both giving good agreement with experiment.
  • The hcp-bcc phase boundary has also been computed and is found to be in agreement with experimental observation.
  • Again, only slight differences are found between the LDA and GGA.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17129123.001).
  • [ISSN] 0021-9606
  • [Journal-full-title] The Journal of chemical physics
  • [ISO-abbreviation] J Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Tai KP, Dai XD, Shen YX, Liu BX: Formation and structural anomaly of the metastable phases in an immiscible Ag-Mo system studied by ion beam mixing and molecular dynamics simulation. J Phys Chem B; 2006 Jan 12;110(1):595-606
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Formation and structural anomaly of the metastable phases in an immiscible Ag-Mo system studied by ion beam mixing and molecular dynamics simulation.
  • For the equilibrium immiscible Ag-Mo system characterized by a large positive heat of formation, the nanosized Ag-Mo multilayered samples are designed and prepared to include sufficient interfacial free energy to elevate their initial energetic states to be higher than that of either the amorphous phase or solid solution and then subject to 200 keV xenon ion irradiation.
  • The results show that a uniform amorphous alloy can be obtained within a composition range, at least, from 25 to 88 atom % of Mo.
  • Interestingly, in the intermediate stage of ion irradiation, a bcc phase, an amorphous phase, and an order (bcc)-disorder coexisting state appear simultaneously in the Ag12Mo88 multilayered sample and extend over the entire bright field image with unanimously homogeneous composition.
  • In thermodynamic modeling, a Gibbs free energy diagram of the Ag-Mo system is constructed, based on Miedema's model, and suggests that within a narrow composition regime of 85-90 atom % of Mo, the energy difference between the bcc and the amorphous phases is extremely small, which is probably the very reason for the order-disorder coexisting state to appear.
  • In atomistic modeling, an ab initio derived Ag-Mo potential is applied to perform molecular dynamics simulations.
  • The simulations not only determine an intrinsic glass-forming ability/range (GFA/GFR) of the Ag-Mo system to be from 10 to 88 atom % of Mo but also reveal the possibility of the formation/appearance of a crystalline and amorphous mixture in a narrow composition regime of 88-92 atom % of Mo.
  • Apparently, the theoretical results are in excellent agreement and/or compatible with the experimental observations in ion beam mixing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16471572.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Alberti C: Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features. G Chir; 2010 Nov-Dec;31(11-12):568-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While, some time ago, NE cells have been considered as derived from progenitor neural crest cells, currently are thought to arise, as well as both basal and secretory cells of prostate gland, from common pluripotent stem cells.
  • NE cell are nonproliferative, terminally differentiated, PSA/acid phosphatase and androgen receptor (AR)-negative cells, moreover exhibiting an antiapoptotic phenotype due to survivin expression.
  • NE differentiation in prostate malignancy arises in three different forms: carcinoid, oat cell carcinoma, focally NE-differentiated conventional tumor.
  • Selective expression of stem cell-associated markers, such as CD44/Oct4A gene, in NE cancerous cells explain their therapy escape together with tumor recurrence and metastasis.
  • Malignant NE cells, although unable to proliferate, increase the proliferation of the neighboring nonneuroendocrine cancer cells, by providing them with hormone peptide-mediated growth paracrine stimuli.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / physiopathology. Cell Transdifferentiation. Prostatic Neoplasms / pathology. Prostatic Neoplasms / physiopathology
  • [MeSH-minor] Androgen Antagonists / therapeutic use. Androgens / metabolism. Antineoplastic Agents, Hormonal / therapeutic use. Apoptosis / drug effects. Biomarkers / metabolism. Cell Transformation, Neoplastic / drug effects. Chromogranins / metabolism. Humans. Male. Neoplasm Invasiveness. Phosphopyruvate Hydratase / metabolism. Pluripotent Stem Cells / metabolism. Prognosis. Prostate-Specific Antigen / metabolism. Receptors, Androgen / metabolism. Treatment Failure


64. Bunyapaiboonsri T, Yoiprommarat S, Khonsanit A, Komwijit S: Phenolic glycosides from the filamentous fungus Acremonium sp. BCC 14080. J Nat Prod; 2008 May;71(5):891-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenolic glycosides from the filamentous fungus Acremonium sp. BCC 14080.
  • New phenolic mono- and digalactopyranosides (1 and 2), their aglycone KS-501a (3), and a new phenolic 4-O-methylglucopyranoside (4) were isolated from the filamentous fungus Acremonium sp. BCC 14080.
  • Structures of these compounds were elucidated by extensive MS and NMR spectroscopic analyses.
  • Compound 1 displayed anti-HSV-1 activity with an IC(50) value of 7.2 microM.
  • Compound 3 exhibited activity against Plasmodium falciparum K1 with an IC(50) value of 9.9 microM.
  • [MeSH-major] Acremonium / chemistry. Antiviral Agents / isolation & purification. Antiviral Agents / pharmacology. Glycosides / isolation & purification. Glycosides / pharmacology. Herpesvirus 1, Human / drug effects. Phenols / isolation & purification. Phenols / pharmacology. Plasmodium falciparum / drug effects
  • [MeSH-minor] Animals. Cercopithecus aethiops. Drug Screening Assays, Antitumor. Humans. Hydroxybenzoates / chemistry. Hydroxybenzoates / isolation & purification. Hydroxybenzoates / pharmacology. Inhibitory Concentration 50. Molecular Structure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363379.001).
  • [ISSN] 0163-3864
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Glycosides; 0 / Hydroxybenzoates; 0 / Phenols; 120634-86-8 / KS 501
  •  go-up   go-down


65. Iijima M, Brantley WA, Baba N, Alapati SB, Yuasa T, Ohno H, Mizoguchi I: Micro-XRD study of beta-titanium wires and infrared soldered joints. Dent Mater; 2007 Sep;23(9):1051-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micro-XRD study of beta-titanium wires and infrared soldered joints.
  • OBJECTIVE: The purpose of this study was to investigate the metallurgical phases in beta-titanium soldered joints prepared by infrared soldering, using the Micro X-ray diffraction technique (Micro-XRD), and to characterize the Vickers hardness in the soldered beta-titanium wires.
  • METHODS: Beta-titanium wires with cross-section dimensions of 0.032in.x0.032in. (TMA, Ormco), and both titanium-based solder (Ti-30Ni-20Cu, Selec) and silver-based solder (Ag-22Cu-17Zn-5Sn, Tomy) were selected.
  • Soldering was performed using infrared radiation (RS-1, Morita) under argon atmosphere.
  • Micro-XRD analyses were performed at room temperature.
  • Micro-XRD spectra were obtained for the boundary region of the soldered beta-titanium wires using 50microm and 10microm diameter analysis regions.
  • Hardness was measured at 30microm intervals from boundary of the diffusion layer and beta-titanium wire.
  • The Kruskal-Wallis test with the Bonferroni and Wilcoxson Mann-Whitney tests for nonparametric means were employed as statistical methods (P<0.05).
  • RESULTS: For both types of soldered beta-titanium samples, the Micro-XRD spectra contained four major peaks for body-centered cubic (bcc) beta-titanium.
  • Additional peaks at about 41 and 45 degrees are attributed to Cu-Ti intermetallic phase(s), which may be metastable under soldering conditions.
  • The diffusion layer had greater hardness than bulk beta-titanium for both types of soldered specimens (P<0.05).
  • SIGNIFICANCE: Soldering of beta-titanium orthodontic wire by infrared radiation may be acceptable for clinical use, since Micro-XRD spectra revealed that both types of soldered specimens largely retained the bcc beta-titanium structure.
  • Further research is needed to investigate the mechanical properties and corrosion behavior of infrared-soldered beta-titanium wire.
  • [MeSH-major] Dental Soldering. Orthodontic Wires. Titanium / chemistry
  • [MeSH-minor] Alloys / chemistry. Copper / chemistry. Diffusion. Electron Probe Microanalysis. Hardness. Humans. Infrared Rays. Materials Testing. Mechanics. Metallurgy. Microspectrophotometry. Nickel / chemistry. Silver / chemistry. Surface Properties. Tin / chemistry. X-Ray Diffraction. Zinc / chemistry

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICKEL, ELEMENTAL .
  • Hazardous Substances Data Bank. SILVER, ELEMENTAL .
  • Hazardous Substances Data Bank. TIN .
  • Hazardous Substances Data Bank. TITANIUM .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178150.001).
  • [ISSN] 0109-5641
  • [Journal-full-title] Dental materials : official publication of the Academy of Dental Materials
  • [ISO-abbreviation] Dent Mater
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alloys; 3M4G523W1G / Silver; 7440-31-5 / Tin; 789U1901C5 / Copper; 7OV03QG267 / Nickel; D1JT611TNE / Titanium; J41CSQ7QDS / Zinc
  •  go-up   go-down


66. Pinto Pereira SM, Hipwell JH, McCormack VA, Tanner C, Moss SM, Wilkinson LS, Khoo LA, Pagliari C, Skippage PL, Kliger CJ, Hawkes DJ, Silva IM: Automated registration of diagnostic to prediagnostic x-ray mammograms: evaluation and comparison to radiologists' accuracy. Med Phys; 2010 Sep;37(9):4530-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five mammography film readers independently identified landmarks (tumor, nipple, and usually two other normal features) on pairs of diagnostic and corresponding prediagnostic digitized images from 52 breast cancer cases.
  • Mean accuracy (mm) of the affine registration varied between 3.16 (95% CI 2.56, 3.90) for nipple points in breasts with density 20%-39% and 5.73 (4.80, 6.84) for tumor points in breasts with density < 20%.
  • [MeSH-major] Breast Neoplasms / diagnostic imaging. Image Processing, Computer-Assisted / methods. Mammography / methods. Radiology / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20964170.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Woditschka S, Habel LA, Udaltsova N, Friedman GD, Sieh W: Lipophilic statin use and risk of breast cancer subtypes. Cancer Epidemiol Biomarkers Prev; 2010 Oct;19(10):2479-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted a large case-control study within Kaiser Permanente of Northern California (KPNC) to determine whether chronic use of lipophilic statins is associated with decreased risk of HR-negative breast cancer or other breast cancer subtypes.
  • Women who used lipophilic statins did not have a decreased risk of HR-negative breast cancer (odds ratio(adj), 0.98; 95% CI, 0.84-1.14) nor altered risk of HR-positive disease (odds ratio(adj), 1.03; 95% CI, 0.97-1.10).

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Ann Med. 2000 Apr;32(3):164-76 [10821323.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):416-21 [17372235.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):18-27 [11134191.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):453-9 [12663504.001]
  • [Cites] Menopause. 2003 Jul-Aug;10(4):332-6 [12851516.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1887-98 [15180944.001]
  • [Cites] Cancer Lett. 2007 Jun 8;250(2):220-8 [17125918.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2008 Jan;17(1):27-36 [17944002.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1832-41 [18067133.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1026-7 [18463398.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1028-33 [18463402.001]
  • [Cites] BMJ. 2008;337:a540 [18621762.001]
  • [Cites] Oncology (Williston Park). 2008 Oct;22(11):1233-9; discussion 1239-40, 1243 [18980022.001]
  • [Cites] Eur J Cancer. 2008 Oct;44(15):2122-32 [18707867.001]
  • [Cites] Int J Cancer. 2009 Feb 1;124(3):698-712 [18988226.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Feb;2(2):161-7 [19196723.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Ann Med. 1991 Dec;23(6):643-8 [1777219.001]
  • [Cites] Am J Public Health. 1992 May;82(5):703-10 [1566949.001]
  • [Cites] Lancet. 1996 Jun 22;347(9017):1713-27 [8656904.001]
  • [Cites] Epidemiology. 1997 May;8(3):275-80 [9115022.001]
  • [Cites] Lancet. 1997 Oct 11;350(9084):1047-59 [10213546.001]
  • [Cites] Lancet. 2005 Jan 1-7;365(9453):82-93 [15639683.001]
  • [Cites] Fundam Clin Pharmacol. 2005 Feb;19(1):117-25 [15660968.001]
  • [Cites] Arch Intern Med. 2005 Oct 24;165(19):2264-71 [16246993.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):930-42 [16341084.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):74-80 [16391219.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2006 May;15(5):291-303 [16447304.001]
  • [Cites] J Natl Cancer Inst. 2006 May 17;98(10):700-7 [16705124.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8707-14 [16951186.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):118-45 [17159189.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):833-43 [17131313.001]
  • [ErratumIn] Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):1001-3
  • (PMID = 20729289.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098838; United States / NCI NIH HHS / CA / R01 CA 098838
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ NIHMS231480; NLM/ PMC2952055
  •  go-up   go-down


68. Surov A, Holzhausen HJ, Ruschke K, Arnold D, Spielmann RP: Breast plasmacytoma. Acta Radiol; 2010 Jun;51(5):498-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: In conclusion, BP does not have specific radiological or clinical features and can be misdiagnosed as primary breast carcinoma or even as a benign process.
  • [MeSH-major] Breast Neoplasms / diagnosis. Plasmacytoma / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / diagnosis. Breast Neoplasms, Male / epidemiology. Breast Neoplasms, Male / etiology. Diagnosis, Differential. Female. Germany / epidemiology. Humans. Incidental Findings. Magnetic Resonance Imaging. Male. Mammography. Middle Aged. Multiple Myeloma / complications. Prevalence. Retrospective Studies. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429767.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Yang H, Zhao JS, Hawari J: Effect of 2,4-dinitrotoluene on the anaerobic bacterial community in marine sediment. J Appl Microbiol; 2009 Dec 1;107(6):1799-808
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of 2,4-dinitrotoluene on the anaerobic bacterial community in marine sediment.
  • AIMS: To study the impact of added 2,4-dinitrotoluene (DNT) on the anaerobic bacterial community in marine sediment collected from an unexploded ordnance dumping site in Halifax Harbour.
  • METHODS AND RESULTS: Marine sediment was spiked with 2,4-DNT and incubated under anaerobic conditions in the presence and absence of lactate.
  • Indigenous bacteria in the sediment removed 2,4-DNT with subsequent formation of its mono- and diamino-derivatives under both conditions.
  • PCR-DGGE and nucleotide sequencing were used to monitor the change in the bacterial population in sediment caused by the presence of 2,4-DNT.
  • The results showed that denaturing gradient gel electrophoresis banding patterns of sediment microcosms treated with 2,4-DNT were different from controls that did not receive 2,4-DNT.
  • Bacteroidetes, Firmicutes and delta-Proteobacteria were present in sediment incubated in the absence of 2,4-DNT.
  • However, several gamma-Proteobacteria became dominant in sediment in the presence of 2,4-DNT, two of which were 99% similar to Shewanella canadensis and Shewanella sediminis.
  • In the presence of both 2,4-DNT and lactate, two additional delta-Proteobacteria were enriched, one closely related (98% similarity) to Desulfofrigus fragile and the other affiliated (96% similarity) to Desulfovibrio sp.
  • In contrast, none of the above four Proteobacteria were enriched in sediment incubated with lactate alone.
  • CONCLUSIONS: Presence of 2,4-DNT led to a significant change in bacterial population of marine sediment with the enrichment of several gamma- and delta-Proteobacteria.
  • SIGNIFICANCE AND IMPACT OF THE STUDY: Our results provided the first evidence on the impact of the pollutant 2,4-DNT on the indigenous bacterial community in marine sediment, and provided an insight into the composition of bacterial community that degrade 2,4-DNT.
  • [MeSH-major] Bacteria, Anaerobic / drug effects. Bacteria, Anaerobic / isolation & purification. Dinitrobenzenes / toxicity. Geologic Sediments / microbiology. Water Pollutants, Chemical / toxicity
  • [MeSH-minor] Canada. DNA, Bacterial / genetics. Electrophoresis, Polyacrylamide Gel. Phylogeny. RNA, Ribosomal, 16S / genetics

  • Hazardous Substances Data Bank. 2,4-DINITROTOLUENE .
  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19486208.001).
  • [ISSN] 1365-2672
  • [Journal-full-title] Journal of applied microbiology
  • [ISO-abbreviation] J. Appl. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / Dinitrobenzenes; 0 / RNA, Ribosomal, 16S; 0 / Water Pollutants, Chemical; 6741D310ED / 2,4-dinitrotoluene
  •  go-up   go-down


70. Sanguin H, Remenant B, Dechesne A, Thioulouse J, Vogel TM, Nesme X, Moënne-Loccoz Y, Grundmann GL: Potential of a 16S rRNA-based taxonomic microarray for analyzing the rhizosphere effects of maize on Agrobacterium spp. and bacterial communities. Appl Environ Microbiol; 2006 Jun;72(6):4302-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential of a 16S rRNA-based taxonomic microarray for analyzing the rhizosphere effects of maize on Agrobacterium spp. and bacterial communities.
  • Bacterial diversity is central to ecosystem sustainability and soil biological function, for which the role of roots is important.
  • The high-throughput analysis potential of taxonomic microarray should match the breadth of bacterial diversity.
  • Here, the power of this technology was evidenced through methodological verifications and analysis of maize rhizosphere effect based on a 16S rRNA-based microarray developed from the prototype of H.
  • Sanguin et al. (Environ. Microbiol.
  • 8:289-307, 2006).
  • The current probe set was composed of 170 probes (41 new probes in this work) that targeted essentially the Proteobacteria.
  • Cloning and sequencing of 16S rRNA amplicons were carried out on maize rhizosphere and bulk soil DNA.
  • All tested clones that had a perfect match with corresponding probes were positive in the hybridization experiment.
  • The hierarchically nested probes were reliable, but the level of taxonomic identification was variable, depending on the probe set specificity.
  • The comparison of experimental and theoretical hybridizations revealed 0.91% false positives and 0.81% false negatives.
  • The microarray detection threshold was estimated at 0.03% of a given DNA type based on DNA spiking experiments.
  • A comparison of the maize rhizosphere and bulk soil hybridization results showed a significant rhizosphere effect, with a higher predominance of Agrobacterium spp. in the rhizosphere, as well as a lower prevalence of Acidobacteria, Bacteroidetes, Verrucomicrobia, and Planctomycetes, a new taxon of interest in soil.
  • In addition, well-known taxonomic groups such as Sphingomonas spp., Rhizobiaceae, and Actinobacteria were identified in both microbial habitats with strong hybridization signals.
  • The taxonomic microarray developed in the present study was able to discriminate and characterize bacterial community composition in related biological samples, offering extensive possibilities for systematic exploration of bacterial diversity in ecosystems.
  • [MeSH-major] Proteobacteria / classification. Proteobacteria / genetics. RNA, Bacterial / genetics. RNA, Ribosomal, 16S / genetics. Rhizobium / classification. Rhizobium / genetics. Zea mays / microbiology
  • [MeSH-minor] Cloning, Molecular. Oligonucleotide Array Sequence Analysis. Phylogeny. Polymerase Chain Reaction. Soil Microbiology

  • COS Scholar Universe. author profiles.
  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Microbiol. 2004 Aug;12(8):386-93 [15276615.001]
  • [Cites] J Ind Microbiol Biotechnol. 2004 Jul;31(6):278-88 [15221668.001]
  • [Cites] BMC Bioinformatics. 2004 Jul 29;5:103 [15283861.001]
  • [Cites] Appl Environ Microbiol. 2004 Sep;70(9):5094-101 [15345387.001]
  • [Cites] Bioinformatics. 2004 Sep 22;20(14):2317-9 [15073015.001]
  • [Cites] Syst Appl Microbiol. 1999 Sep;22(3):434-44 [10553296.001]
  • [Cites] Nature. 2000 May 11;405(6783):228-33 [10821283.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):9834-9 [10963655.001]
  • [Cites] Environ Microbiol. 2001 Jan;3(1):19-31 [11225720.001]
  • [Cites] Appl Environ Microbiol. 2001 May;67(5):2284-91 [11319113.001]
  • [Cites] Appl Microbiol Biotechnol. 2001 Jul;56(1-2):40-57 [11499947.001]
  • [Cites] Appl Environ Microbiol. 2001 Oct;67(10):4708-16 [11571176.001]
  • [Cites] Appl Environ Microbiol. 2001 Oct;67(10):4742-51 [11571180.001]
  • [Cites] Appl Environ Microbiol. 2001 Dec;67(12):5780-90 [11722935.001]
  • [Cites] Appl Environ Microbiol. 2002 Mar;68(3):1425-30 [11872496.001]
  • [Cites] Appl Environ Microbiol. 2002 May;68(5):2391-6 [11976113.001]
  • [Cites] Appl Environ Microbiol. 2002 May;68(5):2535-41 [11976131.001]
  • [Cites] Appl Environ Microbiol. 1999 Apr;65(4):1662-9 [10103265.001]
  • [Cites] Can J Microbiol. 2004 Jul;50(7):469-74 [15381970.001]
  • [Cites] Microb Ecol. 2004 Apr;47(3):243-51 [14994173.001]
  • [Cites] Appl Environ Microbiol. 1992 Oct;58(10):3413-6 [1444376.001]
  • [Cites] Appl Environ Microbiol. 1995 Jun;61(6):2270-5 [7793948.001]
  • [Cites] Microbiology. 1995 Jul;141 ( Pt 7):1493-506 [7551018.001]
  • [Cites] Gene. 1995 Nov 7;165(1):81-6 [7489921.001]
  • [Cites] J Bacteriol. 1996 Jun;178(12):3496-500 [8655546.001]
  • [Cites] FEMS Microbiol Lett. 1997 Aug 1;153(1):181-90 [9252585.001]
  • [Cites] Appl Environ Microbiol. 1997 Nov;63(11):4516-22 [9361437.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6578-83 [9618454.001]
  • [Cites] J Bacteriol. 1998 Sep;180(18):4765-74 [9733676.001]
  • [Cites] Microbiology. 1998 Dec;144 ( Pt 12):3257-66 [9884217.001]
  • [Cites] Science. 1999 Oct 15;286(5439):542-4 [10521351.001]
  • [Cites] Appl Environ Microbiol. 2004 Dec;70(12):6998-7009 [15574893.001]
  • [Cites] Appl Environ Microbiol. 2004 Dec;70(12):7161-72 [15574913.001]
  • [Cites] Appl Environ Microbiol. 2005 Feb;71(2):826-34 [15691937.001]
  • [Cites] Appl Environ Microbiol. 2005 Mar;71(3):1373-86 [15746340.001]
  • [Cites] J Microbiol Methods. 2005 Jul;62(1):37-56 [15823393.001]
  • [Cites] FEMS Microbiol Lett. 2005 Apr 15;245(2):271-8 [15837382.001]
  • [Cites] Annu Rev Plant Biol. 2005;56:15-39 [15862088.001]
  • [Cites] J Exp Bot. 2005 Jul;56(417):1761-78 [15911555.001]
  • [Cites] BMC Genomics. 2005;6:78 [15918914.001]
  • [Cites] Appl Environ Microbiol. 2005 Nov;71(11):6910-7 [16269725.001]
  • [Cites] FEMS Microbiol Ecol. 2005 Feb 1;51(3):333-40 [16329881.001]
  • [Cites] Environ Microbiol. 2006 Feb;8(2):289-307 [16423016.001]
  • [Cites] Appl Environ Microbiol. 2002 Jul;68(7):3215-25 [12088997.001]
  • [Cites] Annu Rev Phytopathol. 2002;40:309-48 [12147763.001]
  • [Cites] Bioinformatics. 2002;18 Suppl 1:S105-10 [12169537.001]
  • [Cites] Appl Environ Microbiol. 2002 Dec;68(12):6121-8 [12450836.001]
  • [Cites] Mol Ecol. 2003 Jan;12(1):251-62 [12492893.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):514-6 [12520066.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Appl Environ Microbiol. 2003 Mar;69(3):1482-7 [12620832.001]
  • [Cites] Appl Environ Microbiol. 2003 May;69(5):2684-91 [12732537.001]
  • [Cites] Environ Microbiol. 2003 Jun;5(6):441-52 [12755711.001]
  • [Cites] Environ Microbiol. 2003 Jul;5(7):566-82 [12823189.001]
  • [Cites] Curr Opin Biotechnol. 2003 Jun;14(3):311-8 [12849785.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Environ Microbiol. 2003 Oct;5(10):896-907 [14510843.001]
  • [Cites] Environ Microbiol. 2003 Oct;5(10):933-43 [14510847.001]
  • [Cites] Appl Environ Microbiol. 2003 Oct;69(10):6143-51 [14532074.001]
  • [Cites] Appl Environ Microbiol. 2003 Nov;69(11):6875-87 [14602652.001]
  • [Cites] Appl Environ Microbiol. 2003 Dec;69(12):7354-63 [14660385.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):1363-71 [14985472.001]
  • [Cites] Appl Environ Microbiol. 2004 Mar;70(3):1767-76 [15006803.001]
  • [Cites] Environ Microbiol. 2004 Apr;6(4):347-63 [15008813.001]
  • [Cites] Biotechniques. 2004 Apr;36(4):664-70, 672, 674-5 [15088384.001]
  • [Cites] BMC Biotechnol. 2004 Mar 8;4:3 [15113428.001]
  • [Cites] Environ Microbiol. 2004 Jun;6(6):638-45 [15142252.001]
  • [Cites] Appl Environ Microbiol. 2004 Jun;70(6):3541-51 [15184155.001]
  • [Cites] Curr Opin Microbiol. 2004 Jun;7(3):221-6 [15196488.001]
  • (PMID = 16751545.001).
  • [ISSN] 0099-2240
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Bacterial; 0 / RNA, Ribosomal, 16S
  • [Other-IDs] NLM/ PMC1489601
  •  go-up   go-down


71. Tworoger SS, Missmer SA, Eliassen AH, Spiegelman D, Folkerd E, Dowsett M, Barbieri RL, Hankinson SE: The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev; 2006 May;15(5):967-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / blood. Dehydroepiandrosterone / blood. Dehydroepiandrosterone Sulfate / blood

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702378.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA50385; United States / NCI NIH HHS / CA / CA67262; United States / NCI NIH HHS / CA / P50 CA089393; United States / NCI NIH HHS / CA / R25 CA 098566-2; United States / NCI NIH HHS / CA / T32 CA090001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 459AG36T1B / Dehydroepiandrosterone; 57B09Q7FJR / Dehydroepiandrosterone Sulfate
  •  go-up   go-down


72. Kaplan AL, Weitzul SB, Taylor RS: Longitudinal diminution of tumor size for basal cell carcinoma suggests shifting referral patterns for Mohs surgery. Dermatol Surg; 2008 Jan;34(1):15-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal diminution of tumor size for basal cell carcinoma suggests shifting referral patterns for Mohs surgery.
  • OBJECTIVE: The objective was to examine whether referral patterns for basal cell carcinoma (BCC) at an academic Mohs surgery practice have shifted over recent years toward referral for smaller, lower risk tumors.
  • METHODS: A retrospective longitudinal comparison of tumor characteristics was performed for BCCs treated at our institution from a recent year (2004) and a past year (1996).
  • Statistical analyses were used to identify differences in tumor size, distribution by anatomic site, and primary versus recurrent status.
  • A 24% decrease in preoperative tumor surface area was observed from 1996 (1.25 cm2) to 2004 (0.95 cm2).
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Mohs Surgery. Referral and Consultation / trends. Skin Neoplasms / pathology
  • [MeSH-minor] Humans. Longitudinal Studies. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053056.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Barth RN, Janus CA, Lillesand CA, Radke NA, Pirsch JD, Becker BN, Fernandez LA, Thomas Chin L, Becker YT, Odorico JS, D'Alessandro AM, Sollinger HW, Knechtle SJ: Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int; 2006 Nov;19(11):885-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No serious infectious complications were observed and two patients developed basal cell skin cancer.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Immunosuppressive Agents / therapeutic use. Kidney Transplantation / methods. Sirolimus / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Transpl Int. 2006 Nov;19(11):881-4 [17018122.001]
  • (PMID = 17018123.001).
  • [ISSN] 0934-0874
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00365846
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Calcineurin Inhibitors; 0 / Immunosuppressive Agents; 3A189DH42V / alemtuzumab; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


74. Meibodi NT, Maleki M, Javidi Z, Nahidi Y: Clinicopathological evaluation of radiation induced basal cell carcinoma. Indian J Dermatol; 2008;53(3):137-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological evaluation of radiation induced basal cell carcinoma.
  • BACKGROUND: Development of skin neoplasms is one of the most important chronic complications of radiation therapy.
  • Basal cell carcinoma (BCC) is the most frequent carcinoma occurring at the region of the body to which radiotherapy was delivered.
  • AIM: The aim of this study was to evaluate clinical and histological aspects of basal cell carcinoma in patients with a history of radiotherapy.
  • MATERIALS AND METHODS: Medical records and microscopic slides of 80 patients with basal cell carcinoma who had received radiotherapy (1996-2006) were reviewed in pathology department of Imam Reza hospital of Mashhad, Iran.
  • Plaque was the most common clinical pattern of basal cell carcinoma.
  • Histologically, macronodular and pigmented carcinoma were the most predominant forms of basal cell carcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4767-70 [17214338.001]
  • [Cites] Clin Exp Dermatol. 2000 Jul;25(5):381-3 [11012589.001]
  • [Cites] J Craniomaxillofac Surg. 2005 Jun;33(3):197-200 [15878521.001]
  • [Cites] Ann Plast Surg. 2004 Dec;53(6):593-5 [15602259.001]
  • [Cites] Eur J Dermatol. 1998 Apr-May;8(3):180-2 [9649688.001]
  • [Cites] Pediatr Hematol Oncol. 1998 Mar-Apr;15(2):187-91 [9592846.001]
  • [Cites] Tex Med. 1997 Jul;93(7):57-9 [9226992.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1848-53 [8961975.001]
  • [Cites] Radiat Res. 1991 Mar;125(3):318-25 [2000456.001]
  • [Cites] Radiat Res. 1984 Oct;100(1):192-204 [6494429.001]
  • [Cites] Cancer Radiother. 2004 Aug;8(4):270-3 [15450522.001]
  • [Cites] Eur J Dermatol. 2004 May-Jun;14(3):182-5 [15246946.001]
  • [Cites] Cancer Radiother. 2004 Apr;8(2):81-7 [15063875.001]
  • [Cites] Dermatol Surg. 2003 Dec;29(12):1233-5 [14725670.001]
  • [Cites] Radiat Res. 2002 Apr;157(4):410-8 [11893243.001]
  • [Cites] Dermatol Surg. 2001 Jul;27(7):667-9 [11442620.001]
  • [Cites] Presse Med. 2006 Jan;35(1 Pt 1):55-7 [16462665.001]
  • (PMID = 19882013.001).
  • [ISSN] 1998-3611
  • [Journal-full-title] Indian journal of dermatology
  • [ISO-abbreviation] Indian J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2763736
  • [Keywords] NOTNLM ; Basal cell carcinoma / basal cell epithelioma / radiotherapy
  •  go-up   go-down


75. Oh ST, Schramme A, Stark A, Tilgen W, Gutwein P, Reichrath J: The disintegrin-metalloproteinases ADAM 10, 12 and 17 are upregulated in invading peripheral tumor cells of basal cell carcinomas. J Cutan Pathol; 2009 Apr;36(4):395-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The disintegrin-metalloproteinases ADAM 10, 12 and 17 are upregulated in invading peripheral tumor cells of basal cell carcinomas.
  • BACKGROUND: Members of the a disintegrin and metalloproteinase (ADAM) family are expressed in malignant tumors and participate in the pathogenesis of cancer.
  • However, the presence of ADAM 10, 12, 17 and their role in basal cell carcinoma (BCC) have not been described.
  • RESULTS: Immunoreactivity of ADAM 10, 12 and 17 was increased at the peripheral tumor margin compared with central areas of BCC tumor cell nests.
  • Immunoreactivity of ADAM 10 and 12 was increased in the deep margin of invading tumor cell nests in mixed BCC.
  • Focally increased expression of ADAM 12 was detected in squamous differentiated tumor cells of nodular BCC.
  • [MeSH-major] ADAM Proteins / biosynthesis. Amyloid Precursor Protein Secretases / biosynthesis. Carcinoma, Basal Cell / enzymology. Membrane Proteins / biosynthesis. Skin Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19278423.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 3.4.- / Amyloid Precursor Protein Secretases; EC 3.4.24.- / ADAM 12 protein; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / tumor necrosis factor-alpha convertase; EC 3.4.24.81 / ADAM10 protein, human
  •  go-up   go-down


76. Ali F, Brown A, Gottwald L, Thomas J: Basal cell carcinoma with matrical differentiation in a transplant patient: a case report and review of the literature. J Cutan Pathol; 2005 Jul;32(6):445-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with matrical differentiation in a transplant patient: a case report and review of the literature.
  • BACKGROUND: Shadow cells, characterized by basaloid squamous cells with a distinct well-defined border and a central unstained area as a shadow of lost nuclei, are characteristic of pilomatricoma, a distinct neoplasm of hair matrix differentiation.
  • The presence of shadow cells within tumor islands composed of follicular germinative cells of an otherwise classic basal cell carcinoma (BCC) has been considered as a distinct diagnostic category of BCC with matrical differentiation.
  • In these areas, the tumor nodules were connected to the epidermis, whereas in others, it extended deep into the reticular dermis to the subcutaneous fat junction.
  • Elsewhere, the majority of the tumor contained a population of shadow cells, similar to those in pilomatricoma, with basaloid-appearing matrical cells in the periphery.
  • Areas of cystic degeneration were present throughout the tumor.
  • CONCLUSION: BCC with matrical differentiation is a distinct pathologic entity and a rare subtype of BCC featuring shadow and matrical cells, typically seen in pilomatricoma, a benign hair matrix neoplasm.
  • This tumor has not yet been reported in an immunosuppressed transplant patient.
  • [MeSH-major] Carcinoma, Basal Cell / immunology. Carcinoma, Basal Cell / pathology. Heart Transplantation. Immunocompromised Host. Skin Neoplasms / immunology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953381.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


77. Khaled A, Ben Mbarek L, Zeglaoui F, Ezzine N, Fazaa B, Kamoun MR: [Epidemiologic study of cutaneous cancers in aged persons]. Tunis Med; 2008 Oct;86(10):895-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Basal cell carcinoma (BCC) represented 68.2% of all cutaneous cancers in aged persons and 53.84% of all BCC independently of age.
  • Squamous cell carcinoma (SCC) represented 23.5% of all cutaneous cancers in aged persons and 67.44% of all SCC independently of age.
  • Through this study we conclude that the geriatric patient is at a high risk of developing cutaneous neoplasms especially carcinomas.
  • [MeSH-major] Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19472808.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


78. Franz M, Spiegel K, Umbreit C, Richter P, Codina-Canet C, Berndt A, Altendorf-Hofmann A, Koscielny S, Hyckel P, Kosmehl H, Virtanen I, Berndt A: Expression of Snail is associated with myofibroblast phenotype development in oral squamous cell carcinoma. Histochem Cell Biol; 2009 May;131(5):651-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Snail is associated with myofibroblast phenotype development in oral squamous cell carcinoma.
  • To investigate the role of Snail in oral squamous cell carcinoma (OSCC), its immunohistochemical expression was analysed in 129 OSCC samples and correlated to nodal metastasis, histological grade, E-cadherin, and alpha smooth-muscle-actin (alpha SMA).
  • The results were compared to findings in 23 basal cell carcinomas (BCC).
  • Additionally, the influence of TGF beta 1 and EGF on Snail, E-cadherin, vimentin, and alpha SMA expression was analysed in two OSCC cell lines.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Squamous Cell / metabolism. Fibroblasts / metabolism. Mouth Neoplasms / metabolism. Myoblasts / metabolism. Transcription Factors / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Rep. 2007 Mar;17 (3):517-23 [17273727.001]
  • [Cites] J Histochem Cytochem. 2006 Nov;54(11):1263-75 [16899764.001]
  • [Cites] Clin Chim Acta. 2007 Aug;383(1-2):51-6 [17537414.001]
  • [Cites] Nephrol Dial Transplant. 2006 Sep;21(9):2549-55 [16757496.001]
  • [Cites] Am J Dermatopathol. 1994 Jun;16(3):258-67 [7943632.001]
  • [Cites] Cell Cycle. 2007 Mar 15;6(6):638-42 [17374993.001]
  • [Cites] Invasion Metastasis. 1997;17(5):251-8 [9876219.001]
  • [Cites] Virchows Arch. 2008 Sep;453(3):267-74 [18712413.001]
  • [Cites] Oncogene. 2006 Aug 24;25(37):5134-44 [16568079.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):973-81 [16567498.001]
  • [Cites] Oral Oncol. 2008 Jul;44(7):646-51 [17996483.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2006 Oct 31;86(40):2821-5 [17200014.001]
  • [Cites] Histochem Cell Biol. 2008 Sep;130(3):509-25 [18496706.001]
  • [Cites] J Mol Histol. 2007 Jun;38(3):183-90 [17390227.001]
  • [Cites] Oral Oncol. 2008 May;44(5):509-17 [17826300.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Nucleic Acids Res. 2006 Apr 14;34(7):2077-84 [16617148.001]
  • [Cites] J Pathol. 2003 Jul;200(4):429-47 [12845611.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1535-41 [16273209.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3241-6 [12082640.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1133-8 [17016644.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] J Pathol. 1992 Apr;166(4):375-81 [1517891.001]
  • [Cites] J Clin Invest. 2002 Aug;110(3):341-50 [12163453.001]
  • [Cites] Breast Cancer Res. 2001;3(4):213-7 [11434871.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Mar;23 Suppl 1:S122-7 [18336655.001]
  • [Cites] Cancer Lett. 2008 Jun 18;264(2):256-64 [18329791.001]
  • [Cites] Hum Mol Genet. 2005 Nov 15;14 (22):3361-70 [16203744.001]
  • [Cites] Histochem Cell Biol. 2006 Jul;126(1):125-31 [16344911.001]
  • [Cites] J Cell Sci. 2005 May 15;118(Pt 10):2143-53 [15855236.001]
  • [Cites] Cell Tissue Res. 2006 Jun;324(3):457-66 [16505995.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39209-16 [12161443.001]
  • [Cites] J Clin Invest. 1995 Feb;95(2):859-73 [7532191.001]
  • [Cites] J Clin Invest. 2003 Dec;112(12):1776-84 [14679171.001]
  • [Cites] Hua Xi Kou Qiang Yi Xue Za Zhi. 2001 Dec;19(6):377-9 [12539688.001]
  • [Cites] Mol Cancer Res. 2008 Jan;6(1):10-20 [18234959.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):830-9 [17211838.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):231-4 [14758552.001]
  • [Cites] J Cell Sci. 2003 Feb 1;116(Pt 3):499-511 [12508111.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 May;127(5):286-92 [11355143.001]
  • [Cites] Cells Tissues Organs. 2007;185(1-3):116-22 [17587817.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):391-402 [12547698.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2892-9 [15070660.001]
  • [Cites] J Cell Sci. 2006 Jan 15;119(Pt 2):283-91 [16390868.001]
  • [Cites] Br J Cancer. 2004 Feb 23;90(4):822-32 [14970860.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):153-70 [11812937.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):891-8 [12632084.001]
  • [Cites] Oncol Rep. 2008 Apr;19(4):993-8 [18357387.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1375-83 [16285938.001]
  • [Cites] Virchows Arch. 2002 Mar;440(3):298-303 [11889601.001]
  • (PMID = 19198871.001).
  • [ISSN] 1432-119X
  • [Journal-full-title] Histochemistry and cell biology
  • [ISO-abbreviation] Histochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Snail Family Transcription Factors; 0 / Transcription Factors; 0 / Transforming Growth Factor beta1; 0 / Vimentin; 62229-50-9 / Epidermal Growth Factor; 68238-35-7 / Keratins
  •  go-up   go-down


79. Nagaraj NS, Zacharias W: Cigarette smoke condensate increases cathepsin-mediated invasiveness of oral carcinoma cells. Toxicol Lett; 2007 Apr 25;170(2):134-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lysosomal cathepsin proteases play important roles in tumor progression, invasion and metastasis.
  • In the present work we investigated the effects of cigarette smoke condensate (CSC) on cathepsin (B, D and L) expression and protease-mediated invasiveness in human oral squamous cell carcinoma (OSCC) cells.
  • Although cathepsin L had the lowest basal level, it had the highest induction in exposed cells compared to cathepsins B and D.
  • Overall, our results indicate that CSC activates cathepsin B and L proteolytic activity and enhances invasiveness in OSCC cells, a response that may play a role in CSC-mediated tumor progression and metastasis dissemination.

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Biochem Biophys. 1992 Dec;299(2):377-80 [1444478.001]
  • [Cites] Am Rev Respir Dis. 1989 Oct;140(4):958-60 [2802382.001]
  • [Cites] Cancer Metastasis Rev. 1996 Mar;15(1):27-51 [8842478.001]
  • [Cites] J Oral Pathol Med. 2005 Feb;34(2):77-86 [15641986.001]
  • [Cites] Oral Oncol. 2005 Mar;41(3):244-60 [15743687.001]
  • [Cites] J Med Invest. 2005 Feb;52(1-2):1-9 [15751268.001]
  • [Cites] Arch Biochem Biophys. 2005 Apr 1;436(1):187-95 [15752724.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Apr 29;330(1):194-203 [15781250.001]
  • [Cites] Int Arch Allergy Immunol. 2005 Oct;138(2):169-79 [16192742.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Mar;132(3):171-83 [16362335.001]
  • [Cites] J Exp Ther Oncol. 2005;5(2):145-50 [16471040.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5242-50 [16707449.001]
  • [Cites] Toxicol Lett. 2006 Aug 20;165(2):182-94 [16713138.001]
  • [Cites] Cancer Biother Radiopharm. 2006 Jun;21(3):217-24 [16918298.001]
  • [Cites] Nat Rev Cancer. 2006 Oct;6(10):764-75 [16990854.001]
  • [Cites] COPD. 2004 Apr;1(1):13-23 [16997735.001]
  • [Cites] Apoptosis. 2007 Jan;12(1):125-39 [17136492.001]
  • [Cites] Int J Cancer. 1997 Jan 6;70(1):120-7 [8985100.001]
  • [Cites] Clin Chim Acta. 2000 Feb 15;291(2):113-35 [10675719.001]
  • [Cites] Hum Pathol. 2000 Feb;31(2):149-60 [10685628.001]
  • [Cites] J Biochem Biophys Methods. 2000 Mar 16;42(3):137-51 [10737220.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3397-403 [10910046.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):931-7 [10987253.001]
  • [Cites] Environ Mol Mutagen. 2000;36(2):127-33 [11013411.001]
  • [Cites] Chem Res Toxicol. 2001 Jul;14(7):767-90 [11453723.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Apr;93(4):446-54 [12029284.001]
  • [Cites] Biol Chem. 2003 Mar;384(3):447-55 [12715895.001]
  • [Cites] Cancer Cell. 2004 May;5(5):409-10 [15144947.001]
  • [Cites] Cancer Cell. 2004 May;5(5):443-53 [15144952.001]
  • [Cites] Clin Exp Metastasis. 2004;21(2):91-106 [15168727.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4681-9 [15122332.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1610-6 [15196548.001]
  • [Cites] Gene Ther. 2004 Jul;11(13):1040-7 [15164093.001]
  • [Cites] J Lab Clin Med. 1989 Oct;114(4):419-25 [2794755.001]
  • [Cites] FEBS Lett. 1993 Nov 22;334(3):340-2 [8243643.001]
  • (PMID = 17399918.001).
  • [ISSN] 0378-4274
  • [Journal-full-title] Toxicology letters
  • [ISO-abbreviation] Toxicol. Lett.
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / DE013150-05; United States / NIDCR NIH HHS / DE / R01 DE013150; United States / NIDCR NIH HHS / DE / DE13150; United States / NIDCR NIH HHS / DE / R01 DE013150-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Tars; 0 / tobacco tar; EC 3.4.- / Cathepsins
  • [Other-IDs] NLM/ NIHMS23777; NLM/ PMC1952681
  •  go-up   go-down


80. Beck B, Lehen'kyi V, Roudbaraki M, Flourakis M, Charveron M, Bordat P, Polakowska R, Prevarskaya N, Skryma R: TRPC channels determine human keratinocyte differentiation: new insight into basal cell carcinoma. Cell Calcium; 2008 May;43(5):492-505
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRPC channels determine human keratinocyte differentiation: new insight into basal cell carcinoma.
  • Aberrant keratinocyte differentiation is considered to be a key mechanism in the onset of hyperproliferative dermatological diseases, including basal cell carcinoma (BCC).
  • This study was designed to investigate the role of calcium-permeable TRPC channels in human keratinocyte differentiation and BCC, using a combination of molecular and cell biology approaches, involving electrophysiology and Ca(2+)-imaging, on the HaCaT cell line, primary cultures of normal human keratinocytes, and BCC cells.
  • [MeSH-major] Calcium / metabolism. Carcinoma, Basal Cell / metabolism. Keratinocytes / metabolism. Skin Neoplasms / metabolism. TRPC Cation Channels / physiology
  • [MeSH-minor] Cell Differentiation. Cell Line. Down-Regulation. Electric Conductivity. Endoplasmic Reticulum / metabolism. Humans. Patch-Clamp Techniques. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17920677.001).
  • [ISSN] 0143-4160
  • [Journal-full-title] Cell calcium
  • [ISO-abbreviation] Cell Calcium
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / TRPC Cation Channels; 0 / TRPC4 ion channel; 0 / transient receptor potential cation channel, subfamily C, member 1; SY7Q814VUP / Calcium
  •  go-up   go-down


81. Papa G, Grandi G, Pascone M: Collision tumor of malignant skin cancers: a case of melanoma in basal cell carcinoma. Pathol Res Pract; 2006;202(9):691-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of malignant skin cancers: a case of melanoma in basal cell carcinoma.
  • The coexistence of two malignant skin tumors intermingling in the same histologic specimen is rare.
  • We report a case of melanoma in a basal cell carcinoma collision tumor.
  • The presence of two intermingled neoplasms was confirmed by immunohistochemistry, which showed strong positivity for S-100 and HMB-45.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Antigens, Neoplasm. Carcinoma, Squamous Cell / pathology. Cheek / pathology. Female. Humans. Immunohistochemistry. Melanoma-Specific Antigens. Neoplasm Proteins / metabolism. S100 Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16876964.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


82. Inoue S, Inoue M, Takahashi H, Inoue A, Kunitomo K, Fujii H: [Two advanced/recurrent breast cancer cases effectively treated by trastuzumab/capecitabine combination therapy]. Gan To Kagaku Ryoho; 2008 Feb;35(2):319-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trastuzumab/capecitabine combination therapy was performed for two advanced/recurrent breast cancer cases with acute deterioration of the disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Biomarkers, Tumor / blood. Bone Neoplasms / blood. Bone Neoplasms / drug therapy. Bone Neoplasms / radiography. Bone Neoplasms / secondary. Capecitabine. Female. Humans. Immunotherapy. Liver Neoplasms / blood. Liver Neoplasms / drug therapy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Middle Aged. Neoplasm Staging. Recurrence. Tomography, X-Ray Computed. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281774.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; P188ANX8CK / Trastuzumab; U3P01618RT / Fluorouracil
  •  go-up   go-down


83. Faupel-Badger JM, Sherman ME, Garcia-Closas M, Gaudet MM, Falk RT, Andaya A, Pfeiffer RM, Yang XR, Lissowska J, Brinton LA, Peplonska B, Vonderhaar BK, Figueroa JD: Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland. Br J Cancer; 2010 Sep 28;103(7):1097-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland.
  • Using data from a population-based breast cancer case-control study conducted in two cities in Poland (2000-2003), we examined the association of PRL levels with breast cancer risk factors among controls and with tumour characteristics among the cases.
  • Mean serum PRL levels by tumour characteristics are reported.
  • Levels were not different by tumour size, grade, node involvement or oestrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2 status.
  • [MeSH-major] Breast Neoplasms / blood. Prolactin / blood

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2009 Mar;20(2):253-62 [18853263.001]
  • [Cites] Pituitary. 2008;11(2):209-18 [18404390.001]
  • [Cites] Obesity (Silver Spring). 2006 Sep;14(9):1662-77 [17030978.001]
  • [Cites] Endocrinology. 1999 Nov;140(11):5447-50 [10537179.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Nov;51(5):643-51 [10594527.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1997 Jan;2(1):29-39 [10887517.001]
  • [Cites] Physiol Rev. 2000 Oct;80(4):1523-631 [11015620.001]
  • [Cites] Proc Nutr Soc. 2001 Feb;60(1):81-9 [11310427.001]
  • [Cites] Br J Cancer. 2002 Oct 7;87(8):876-82 [12373602.001]
  • [Cites] Endocr Rev. 2003 Feb;24(1):1-27 [12588805.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6814-9 [15375001.001]
  • [Cites] Int J Cancer. 1976 Apr 15;17(4):441-7 [945228.001]
  • [Cites] Am J Obstet Gynecol. 1977 May 1;128(1):60-74 [403765.001]
  • [Cites] Fertil Steril. 1978 Aug;30(2):141-5 [98356.001]
  • [Cites] Int J Cancer. 1981 Jul 15;28(1):31-4 [7309279.001]
  • [Cites] N Engl J Med. 1987 Jan 29;316(5):229-34 [3099198.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Jul;24(7):1225-31 [3416905.001]
  • [Cites] Med J Aust. 1990 Oct 15;153(8):469-73 [2215338.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2591-5 [7780973.001]
  • [Cites] Cancer Causes Control. 1995 May;6(3):217-24 [7612801.001]
  • [Cites] J Reprod Med. 1995 Aug;40(8):556-60 [7473451.001]
  • [Cites] Gynecol Obstet Invest. 1997;44(2):124-6 [9286727.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):629-34 [10203283.001]
  • [Cites] Endocr Relat Cancer. 1999 Sep;6(3):389-404 [10516853.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2641-7 [16284390.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2476-82 [16489055.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):972-8 [16702379.001]
  • [Cites] Br J Cancer. 2006 Jul 3;95(1):123-9 [16755295.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):325-35 [16900392.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2494-501 [17164375.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1536-41 [17211859.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):439-43 [17372238.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1482-8 [17372279.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):895-9 [17507612.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1079-85 [17487843.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10608-17 [17968031.001]
  • [Cites] Mol Cell Endocrinol. 2008 Jan 16;281(1-2):9-18 [18022314.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):43-50 [18199710.001]
  • [Cites] Breast Cancer Res Treat. 2008 Mar;108(1):57-67 [17468953.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):41-53 [18246319.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1880-3 [18708375.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):938-46 [20332276.001]
  • (PMID = 20736944.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 9002-62-4 / Prolactin
  • [Other-IDs] NLM/ PMC2965860
  •  go-up   go-down


84. Hashimoto K, Yonemori K, Katsumata N, Hotchi M, Kouno T, Shimizu C, Tamura K, Ando M, Takeuchi M, Fujiwara Y: Factors that affect the duration of the interval between the completion of palliative chemotherapy and death. Oncologist; 2009 Jul;14(7):752-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Neoplasms / drug therapy. Palliative Care / methods

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596665.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Dünnebier T, Bermejo JL, Haas S, Fischer HP, Pierl CB, Justenhoven C, Brauch H, Baisch C, Gilbert M, Harth V, Spickenheuer A, Rabstein S, Pesch B, Brüning T, Ko YD, Hamann U: Common variants in the UBC9 gene encoding the SUMO-conjugating enzyme are associated with breast tumor grade. Int J Cancer; 2009 Aug 1;125(3):596-602
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common variants in the UBC9 gene encoding the SUMO-conjugating enzyme are associated with breast tumor grade.
  • Genetic variability may affect expression and activity of UBC9 and may have an impact on breast tumor progression.
  • Model selection identified a recessive penetrance model for rs7187167 as the best representation of tumor grade (global p = 0.001).
  • Imputation of SNPs in a 300 kb region around the genotyped SNPs supported rs7187167 as a major contributor to tumor grade.
  • In addition to tumor size, nodal status and estrogen receptor status, multivariate analyses confirmed an independent role of rs7187167 as predictor of tumor grade (p = 0.0003).
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Polymorphism, Single Nucleotide. SUMO-1 Protein / metabolism. Ubiquitin-Conjugating Enzymes / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19358266.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / SUMO-1 Protein; EC 6.3.2.19 / Ubiquitin-Conjugating Enzymes; EC 6.3.2.19 / ubiquitin-conjugating enzyme UBC9
  •  go-up   go-down


86. Lavie O, Barnett-Griness O, Narod SA, Rennert G: The risk of developing uterine sarcoma after tamoxifen use. Int J Gynecol Cancer; 2008 Mar-Apr;18(2):352-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Sarcoma / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / drug therapy. Endometrial Neoplasms / chemically induced. Female. Humans. Incidence. Middle Aged. Registries. Risk Factors


87. Suzuki T, Matsuo K, Hirose K, Hiraki A, Kawase T, Watanabe M, Yamashita T, Iwata H, Tajima K: One-carbon metabolism-related gene polymorphisms and risk of breast cancer. Carcinogenesis; 2008 Feb;29(2):356-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Genetic Predisposition to Disease. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18174236.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid; EC 1.18.1.- / methionine synthase reductase; EC 1.18.1.2 / Ferredoxin-NADP Reductase; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 2.1.1.13 / 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


88. Fair AM, Dai Q, Shu XO, Matthews CE, Yu H, Jin F, Gao YT, Zheng W: Energy balance, insulin resistance biomarkers, and breast cancer risk. Cancer Detect Prev; 2007;31(3):214-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Additional analyses were performed to evaluate whether the association of energy balance measures with breast cancer risk changed after adjustment for IGFs, IGFBP-3, and C-peptide biomarkers.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1997;76(12):1652-4 [9413957.001]
  • [Cites] Eur J Clin Nutr. 2004 Jan;58(1):17-23 [14679362.001]
  • [Cites] Mech Ageing Dev. 1999 Jun 1;109(1):21-34 [10405986.001]
  • [Cites] Clin Chem. 1999 Aug;45(8 Pt 2):1384-90 [10430822.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1496-501 [15941962.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2881-8 [16365005.001]
  • [Cites] J Womens Health Gend Based Med. 1999 Dec;8(10):1265-72 [10643834.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):694-700 [14770423.001]
  • [Cites] Br J Cancer. 1992 Mar;65(3):311-20 [1313689.001]
  • [Cites] Br J Cancer. 1995 Nov;72(5):1065-6 [7577447.001]
  • [Cites] Int J Biochem Cell Biol. 1996 Jun;28(6):619-37 [8673727.001]
  • [Cites] Science. 1997 Jul 25;277(5325):531-2 [9254422.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89 [10995803.001]
  • [Cites] BMJ. 2000 Oct 7;321(7265):847-8 [11021847.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):994-1001 [11286483.001]
  • [Cites] Endocr Relat Cancer. 2001 Sep;8(3):197-209 [11566611.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1207-11 [11700270.001]
  • [Cites] Int J Cancer. 2001 Nov 1;94(3):449-55 [11745429.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):951-8 [11808715.001]
  • [Cites] Lancet Oncol. 2002 May;3(5):298-302 [12067807.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 11):86-95 [12138402.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):705-12 [12163322.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):862-7 [12223430.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):337-46 [12519874.001]
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):65-74 [12708727.001]
  • [Cites] Exerc Sport Sci Rev. 2003 Jul;31(3):144-8 [12882481.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1067-73 [14578144.001]
  • [Cites] Med Sci Sports Exerc. 2003 Nov;35(11):1834-40 [14600547.001]
  • [Cites] Am J Epidemiol. 2003 Dec 1;158(11):1114-22 [14630608.001]
  • [Cites] Int J Cancer. 1998 Dec 18;79(6):624-8 [9842972.001]
  • (PMID = 17646056.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20RR011792; United States / NCRR NIH HHS / RR / P20 RR011792; United States / NCI NIH HHS / CA / R01 CA064277; United States / NIMHD NIH HHS / MD / P20 MD000516; United States / NCI NIH HHS / CA / R01-CA64277; United States / NCI NIH HHS / CA / R01 CA064277-04; United States / NCI NIH HHS / CA / CA064277-04; United States / NIMHD NIH HHS / MD / 5 P20 MD000516-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / C-Peptide; 0 / Insulin-Like Growth Factor Binding Protein 3; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II
  • [Other-IDs] NLM/ NIHMS29979; NLM/ PMC1994998
  •  go-up   go-down


89. Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl CB, Rabstein S, Selinski S, Mueller T, Ickstadt K, Gilbert M, Ko YD, Baisch C, Pesch B, Harth V, Bolt HM, Vollmert C, Illig T, Eils R, Dippon J, Brauch H: Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat; 2008 Mar;108(1):137-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Biomarkers, Tumor / genetics. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Estrogens / metabolism. Genetic Predisposition to Disease


90. Zhu Y, Brown HN, Zhang Y, Holford TR, Zheng T: Genotypes and haplotypes of the methyl-CpG-binding domain 2 modify breast cancer risk dependent upon menopausal status. Breast Cancer Res; 2005;7(5):R745-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genotypes and haplotypes of the methyl-CpG-binding domain 2 modify breast cancer risk dependent upon menopausal status.
  • INTRODUCTION: MBD2, the gene encoding methyl-CpG-binding domain (MBD)2, is a major methylation related gene and functions as a transcriptional repressor that can specifically bind to the methylated regions of other genes.
  • MBD2 may also mediate gene activation because of its potential DNA demethylase activity.
  • The present case-control study investigated associations between two single nucleotide polymorphisms (SNPs) in the MBD2 gene and breast cancer risk.
  • METHODS: DNA samples from 393 Caucasian patients with breast cancer (cases) and 436 matched control individuals, collected in a recently completed breast cancer case-control study conducted in Connecticut, were included in the study.
  • Because no coding SNPs were found in the MBD2 gene, one SNP in the noncoding exon (rs1259938) and another in the intron 3 (rs609791) were genotyped.
  • Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to estimate cancer risk associated with the variant genotypes and the reconstructed haplotypes.
  • RESULTS: The variant genotypes at both SNP loci were significantly associated with reduced risk among premenopausal women (OR = 0.41 for rs1259938; OR = 0.54 for rs609791).
  • Further haplotype analyses showed that the two rare haplotypes (A-C and A-G) were significantly associated with reduced breast cancer risk (OR = 0.40, 95% CI = 0.20-0.83 for A-C; OR = 0.47, 95% CI = 0.26-0.84 for A-G) in premenopausal women.
  • No significant associations were detected in the postmenopausal women and the whole population.
  • CONCLUSION: Our results demonstrate a role for the MBD2 gene in breast carcinogenesis in premenopausal women.
  • These findings suggest that genetic variations in methylation related genes may potentially serve as a biomarker in risk estimates for breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Menopause.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Mar 21;302(4):759-66 [12646234.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):246-53 [2825969.001]
  • [Cites] Cell. 1990 Aug 10;62(3):503-14 [1974172.001]
  • [Cites] Cancer Causes Control. 1992 Jul;3(4):313-22 [1617118.001]
  • [Cites] EXS. 1993;64:425-51 [8380354.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2552-5 [8168078.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6374-82 [7987831.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4525-30 [7553621.001]
  • [Cites] Ann N Y Acad Sci. 1995 Sep 30;768:91-100 [8526389.001]
  • [Cites] J Mol Biol. 1997 Mar 28;267(2):276-88 [9096225.001]
  • [Cites] Nat Genet. 1997 Jul;16(3):256-9 [9207790.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3347-50 [9269993.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2107-10 [9605753.001]
  • [Cites] Nature. 1998 May 28;393(6683):386-9 [9620804.001]
  • [Cites] EMBO J. 1998 Sep 1;17(17):4905-8 [9724627.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6538-47 [9774669.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4515-8 [9788592.001]
  • [Cites] Br J Cancer. 1999 Jan;79(2):251-6 [9888465.001]
  • [Cites] Nature. 1999 Feb 18;397(6720):579-83 [10050851.001]
  • [Cites] Mamm Genome. 1999 Sep;10(9):906-12 [10441743.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):58-61 [10471499.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):62-6 [10471500.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:213-9 [12724226.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 2;264(3):962-6 [10544038.001]
  • [Cites] Trends Genet. 2000 Jan;16(1):20 [10647297.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):167-74 [10698477.001]
  • [Cites] J Natl Cancer Inst. 2000 May 17;92(10):826-32 [10814678.001]
  • [Cites] FASEB J. 2000 Aug;14(11):1585-94 [10928993.001]
  • [Cites] Am J Hum Genet. 2001 Apr;68(4):978-89 [11254454.001]
  • [Cites] Gene. 2001 Oct 3;276(1-2):73-81 [11591473.001]
  • [Cites] Bioessays. 2001 Dec;23(12):1131-7 [11746232.001]
  • [Cites] Oncol Rep. 2002 Mar-Apr;9(2):393-5 [11836615.001]
  • [Cites] Mol Carcinog. 2002 Mar;33(3):163-71 [11870882.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2704-12 [11965543.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7034-41 [12370825.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):498-504 [12543808.001]
  • [Cites] Cancer. 2004 May 1;100(9):1853-8 [15112265.001]
  • (PMID = 16168120.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA081810; United States / NCI NIH HHS / CA / CA62986; United States / NCI NIH HHS / CA / CA108369; United States / NCI NIH HHS / CA / R03 CA110937; United States / NCI NIH HHS / CA / CA81810; United States / NCI NIH HHS / CA / CA110937; United States / NCI NIH HHS / CA / R03 CA108369
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MBD2 protein, human
  • [Other-IDs] NLM/ PMC1242141
  •  go-up   go-down


91. Zanetti-Dällenbach R, Wight E: [Chemotherapy for gynecological malignancies--a contraindication during pregnancy?]. Ther Umsch; 2005 Jan;62(1):53-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Chemotherapie bei gynäkologischen Tumoren--kontraindiziert in der Schwangerschaft?
  • Even though a malignant tumor during pregnancy is very rare it occurs in 0.02-0.1%.
  • The coincidence of malignant disease with pregnancy leads to an enormous emotional burden to the patient, the couple and the medical staff.
  • Surgery for malignant tumors during pregnancy seems to be save.
  • The most frequent malignant disorders during pregnancy are cervical cancer, breast cancer, melanoma and Hodgkin lymphoma.
  • [MeSH-major] Abnormalities, Drug-Induced / etiology. Abnormalities, Drug-Induced / prevention & control. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / contraindications. Genital Neoplasms, Female / drug therapy. Pregnancy Complications, Neoplastic / drug therapy. Risk Assessment / methods

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Pregnancy and Medicines.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15702707.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 46
  •  go-up   go-down


92. van Oosten EJ, Kuijpers DI, Thissen MR: Different pain sensations in photodynamic therapy of nodular basal cell carcinoma Results from a prospective trial and a review of the literature. Photodiagnosis Photodyn Ther; 2006 Mar;3(1):61-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different pain sensations in photodynamic therapy of nodular basal cell carcinoma Results from a prospective trial and a review of the literature.
  • BACKGROUND: Pain is a major side effect of topical photodynamic therapy (PDT), a relatively new and non-invasive treatment for particular types of basal cell carcinoma (BCC).
  • Furthermore, we studied if gender, tumour size and localization as well as different light sources with comparable wavelengths had an influence on the pain.
  • Gender as well as tumour localization and size did not alter the pain scores.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25049028.001).
  • [ISSN] 1572-1000
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


93. Birch-Johansen F, Jensen A, Mortensen L, Olesen AB, Kjær SK: Trends in the incidence of nonmelanoma skin cancer in Denmark 1978-2007: Rapid incidence increase among young Danish women. Int J Cancer; 2010 Nov 1;127(9):2190-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) were obtained from the Danish Cancer Registry and the Danish Registry of Pathology.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20473901.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


94. Häfner HM, Bräuer K, Radke C, Eichner M, Strölin A: Wavelet analysis of Laser Doppler Flux time series of tumor and inflammatory associated neoangiogenesis. Differences in rhythmical behavior. Clin Hemorheol Microcirc; 2009;43(3):191-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wavelet analysis of Laser Doppler Flux time series of tumor and inflammatory associated neoangiogenesis. Differences in rhythmical behavior.
  • We use continuous wavelet analysis (WA) of Laser Doppler Flux (LDF) time series measured in basal cell carcinomas (BCC) and plaque psoriasis (PP) in order to investigate the rhythmical behavior of blood flow in tumor or inflammatory associated neoangiogenesis.A total of 68 patients with primary BCCs and 40 patients with PP were included in the study.
  • These increases were not found in PP.Rhythmical behavior of blood flow in malignant tumors is totally different from that in regions with inflammation.
  • WA of tumor perfusion could open a new noninvasive monitor system for controlling tumor therapy.
  • [MeSH-major] Microcirculation / physiology. Neoplasms, Basal Cell / blood supply. Psoriasis / physiopathology. Regional Blood Flow / physiology. Skin / blood supply. Skin Neoplasms / blood supply

  • MedlinePlus Health Information. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847053.001).
  • [ISSN] 1875-8622
  • [Journal-full-title] Clinical hemorheology and microcirculation
  • [ISO-abbreviation] Clin. Hemorheol. Microcirc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


95. Boondaeng A, Ishida Y, Tamura T, Tokuyama S, Kitpreechavanich V: Microbispora siamensis sp. nov., a thermotolerant actinomycete isolated from soil. Int J Syst Evol Microbiol; 2009 Dec;59(Pt 12):3136-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microbispora siamensis sp. nov., a thermotolerant actinomycete isolated from soil.
  • An actinomycete, strain DMKUA 245(T), isolated from soil, was investigated using a polyphasic approach.
  • The isolate formed longitudinally paired spores on the tips of short sporophores that branched alternately from aerial hyphae.
  • The morphological and chemotaxonomic properties clearly demonstrated that the new isolate belonged to the genus Microbispora.
  • 16S rRNA gene sequence analysis supported the assignment of the novel strain to the genus Microbispora.
  • The gene sequence similarity values between the novel strain and the closely related species Microbispora corallina, Microbispora rosea subsp. rosea, Microbispora rosea subsp. aerata and Microbispora amethystogenes were 98.4 %, 97.4 %, 97.0 % and 96.9 %, respectively.
  • The DNA-DNA hybridization values and some physiological and biochemical properties indicated that strain DMKUA 245(T) could be distinguished from its phylogenetically closest relatives.
  • Based on these genotypic and phenotypic data, strain DMKUA 245(T) represents a novel species in the genus Microbispora for which the name Microbispora siamensis sp. nov. is proposed.
  • The type strain is strain DMKUA 245(T) (=BCC 14407(T)=NBRC 104113(T)).
  • In addition, DNA-DNA relatedness values in reciprocal hybridization experiments showed that M. amethystogenes was a separate genomic species from M. rosea subsp. rosea.
  • A combination of genotypic and phenotypic data supported the classification of M. amethystogenes as a separate species.
  • [MeSH-major] Actinomycetales / classification. Actinomycetales / isolation & purification. Soil Microbiology
  • [MeSH-minor] DNA, Bacterial / genetics. DNA, Ribosomal / genetics. Hot Temperature. Molecular Sequence Data. Phylogeny. RNA, Ribosomal, 16S / genetics

  • SILVA. SILVA SSU Database .
  • StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19643881.001).
  • [ISSN] 1466-5026
  • [Journal-full-title] International journal of systematic and evolutionary microbiology
  • [ISO-abbreviation] Int. J. Syst. Evol. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ FJ199993
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal; 0 / RNA, Ribosomal, 16S
  •  go-up   go-down


96. Yoon J, Jung SY, Ahn B, Heo K, Jin S, Iyoda T, Yoshida H, Ree M: Order-order and order-disorder transitions in thin films of an amphiphilic liquid crystalline diblock copolymer. J Phys Chem B; 2008 Jul 24;112(29):8486-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Order-order and order-disorder transitions in thin films of an amphiphilic liquid crystalline diblock copolymer.
  • In this study, we quantitatively investigated the temperature-dependent phase transition behaviors of thin films of an interesting amphiphilic diblock copolymer, poly(ethylene oxide)-b-poly(11-[4-(4-butylphenylazo)phenoxy]undecyl methacrylate) (p(EO)-b-p(MAAZ)) and the resulting morphological structures by using synchrotron grazing incidence X-ray scattering (GIXS) and differential scanning calorimetry.
  • The quantitative GIXS analysis showed that the diblock copolymer in the homogeneous, isotropic melt state undergoes phase-separation near 190 degrees C and then forms a body-centered cubic (BCC) structure of spherical p(EO) domains in the p(MAAZ) matrix, at which point the p(EO) domains and the p(MAAZ) matrix are both in amorphous, liquid states.
  • The BCC structure of spherical p(EO) domains is converted to a hexagonal cylinder structure near 120 degrees C, which is induced by the transformation of the isotropic phase of the p(MAAZ) matrix to the smectic A phase, which is composed of a laterally ordered structure of p(MAAZ) blocks with fully extended side groups.
  • The resulting hexagonal cylinder structure is very stable below 120 degrees C.
  • This microscopic hexagonal cylinder structure is retained as the smectic A phase of the p(MAAZ) matrix undergoes further transitions to smectic C near 104 degrees C and to a smectic X phase near 76 degrees C, while the amorphous, liquid phase of the p(EO) cylinders undergoes crystallization near -15 degrees C.
  • These complicated temperature-dependent disorder-order and order-order phase transitions in the films were found to take place reversibly during the heating run.
  • A face-centered orthorhombic structure of p(EO) domains was also found during the heating run and is an intermediate structure in the hexagonal cylinder structure to BCC structure transformation.
  • We use these structural analysis results to propose molecular structure models at various temperatures for thin films of the diblock polymer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18588338.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Madan V, Hoban PR, Strange RC, Fryer AA, Lear JT: Prognostic factors for a subsequent basal cell carcinoma: implications for follow-up. Br J Dermatol; 2006 Jul;155(1):217-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for a subsequent basal cell carcinoma: implications for follow-up.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Br J Dermatol. 2005 Nov;153(5):1078-80 [16225637.001]
  • (PMID = 16792784.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


98. Jiang J, He QQ, Yang XH, Liang Y, Fan LJ, Zhang Y, Guo MQ: Contribution of minute axillary lymph nodes to accurate staging for patients with breast cancer. Chin Med J (Engl); 2007 Oct 20;120(20):1762-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Axillary lymph node metastasis is a very important metastatic pathway in breast cancer and its accurate detection is important for staging tumour and guiding therapy.
  • [MeSH-major] Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Axilla. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18028767.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


99. Dinger JC, Heinemann LA, Möhner S, Thai do M, Assmann A: Breast cancer risk associated with different HRT formulations: a register-based case-control study. BMC Womens Health; 2006;6:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A case-control study was performed within Germany in collaboration with regional cancer registries and tumor centers.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2003 Jun 25;289(24):3254-63 [12824206.001]
  • [Cites] Contraception. 1997 Dec;56(6):373-8 [9494771.001]
  • [Cites] Maturitas. 1999 Nov;33 Suppl 1:S65-72 [10661617.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 16;92(4):328-32 [10675382.001]
  • [Cites] JAMA. 2000 Oct 11;284(14):1837-8 [11025837.001]
  • [Cites] J Epidemiol Community Health. 2000 Nov;54(11):851-8 [11027200.001]
  • [Cites] JAMA. 2002 Jul 17;288(3):321-33 [12117397.001]
  • [Cites] MedGenMed. 2002 Aug 30;4(3):3 [12466746.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1387-92 [12627501.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):419-27 [12927427.001]
  • [Cites] Ann Intern Med. 1992 Dec 15;117(12):1016-37 [1443971.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):721-7 [14999781.001]
  • [Cites] Climacteric. 2003 Dec;6(4):302-10; discussion 310-3 [15006251.001]
  • [Cites] JAMA. 2004 Apr 14;291(14):1701-12 [15082697.001]
  • [Cites] Hum Reprod Update. 2004 Jul-Aug;10(4):281-93 [15192054.001]
  • [Cites] Int J Cancer. 2005 Apr 10;114(3):448-54 [15551359.001]
  • [Cites] Hum Reprod. 2005 Aug;20(8):2052-60 [15932918.001]
  • [Cites] Am J Epidemiol. 2005 Jul 1;162(1):1-2 [15961580.001]
  • [Cites] Cancer Causes Control. 1992 Jul;3(4):355-60 [1617123.001]
  • [Cites] Prev Med. 1991 Jan;20(1):47-63 [1826173.001]
  • [Cites] Am J Epidemiol. 1993 Nov 1;138(9):697-703 [8237985.001]
  • [Cites] Cancer Causes Control. 1995 Sep;6(5):416-24 [8547539.001]
  • [Cites] Maturitas. 1996 May;23 Suppl:S37-45 [8865138.001]
  • [Cites] Ann Intern Med. 1997 Dec 1;127(11):973-80 [9412302.001]
  • [Cites] Lancet. 1997 Oct 11;350(9084):1047-59 [10213546.001]
  • (PMID = 16965641.001).
  • [ISSN] 1472-6874
  • [Journal-full-title] BMC women's health
  • [ISO-abbreviation] BMC Womens Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1574290
  •  go-up   go-down


100. Freier K, Flechtenmacher C, Devens F, Hartschuh W, Hofele C, Lichter P, Joos S: Recurrent NMYC copy number gain and high protein expression in basal cell carcinoma. Oncol Rep; 2006 May;15(5):1141-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent NMYC copy number gain and high protein expression in basal cell carcinoma.
  • Formation of basal cell carcinoma (BCC) has been linked to deregulation in the sonic hedgehogh (Shh) signalling pathway.
  • To assess the expression of Nmyc protein and gene copy numbers of the NMYC gene locus in a representative BCC tumour collection, immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) were performed on 273 BCC specimens of different growth patterns and anatomic localisations on tissue microarray (TMA) sections.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Gene Dosage. Genes, myc / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596176.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down






Advertisement